

# Once-Weekly Semaglutide in Adults with Overweight o

New England Journal of Medicine

384, 989-1002

DOI: [10.1056/nejmoa2032183](https://doi.org/10.1056/nejmoa2032183)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Conference highlights: The 81st Annual (Virtual) conference of the American diabetes association: June 25â€“29, 2021. Journal of Diabetes and Endocrine Practice, 2021, 4, 143.	0.3	0
3	AM833 Is a Novel Agonist of Calcitonin Family G Proteinâ€“Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 417-440.	2.5	27
4	The Role of the Gut Microbiota in the Gutâ€“Brain Axis in Obesity: Mechanisms and Future Implications. International Journal of Molecular Sciences, 2021, 22, 2993.	4.1	26
5	Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 971-984.	13.7	429
6	STEP 1 for Effective Weight Control â€” Another First Step?. New England Journal of Medicine, 2021, 384, 1066-1067.	27.0	10
8	GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk. European Heart Journal, 2021, 42, 1652-1653.	2.2	5
9	The gutâ€“brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. Molecular Metabolism, 2021, 46, 101175.	6.5	29
11	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 325, 1403.	7.4	387
13	Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?. Drugs, 2021, 81, 881-893.	10.9	9
14	Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of nonâ€“alcoholic steatohepatitis. Liver International, 2021, 41, 1853-1866.	3.9	21
15	Finding the sweet spot in the surgical treatment of diabetes in obesity. British Journal of Surgery, 2021, 108, 1011-1013.	0.3	0
16	Practical Approaches to Treating Obesity: Patient and Healthcare Professional Perspectives. Advances in Therapy, 2021, 38, 4138-4150.	2.9	2
17	The STEP 1 trial for weight loss: a step change in treating obesity?. Nature Medicine, 2021, 27, 589-590.	30.7	2
18	Obesity Primer for the Practicing Gastroenterologist. American Journal of Gastroenterology, 2021, 116, 918-934.	0.4	6
19	Can treatment of obesity reduce depression or vice versa?. Journal of Psychiatry and Neuroscience, 2021, 46, E313-E318.	2.4	6
20	Obesity therapeutics: The end of the beginning. Cell Metabolism, 2021, 33, 705-706.	16.2	9
21	Diabetes Drug Aids Weight Reduction in Adults. American Journal of Nursing, 2021, 121, 71-71.	0.4	0
22	Future directions in obesity pharmacotherapy. European Journal of Internal Medicine, 2021, 93, 13-20.	2.2	16

#	ARTICLE	IF	CITATIONS
23	Semaglutide for obesity: four STEPs forward, but more to come. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 252-254.	11.4	8
24	Proglucagon-Derived Peptides as Therapeutics. <i>Frontiers in Endocrinology</i> , 2021, 12, 689678.	3.5	34
25	Treatment options for managing obesity in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 516-523.	2.0	2
26	Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. <i>British Journal of Pharmacology</i> , 2022, 179, 526-541.	5.4	16
27	Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats. <i>Frontiers in Veterinary Science</i> , 2021, 8, 661546.	2.2	0
28	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide-1 Receptor Agonists. <i>Advances in Therapy</i> , 2021, 38, 2821-2839.	2.9	70
29	Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 674704.	3.5	8
31	The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake. <i>Nutrients</i> , 2021, 13, 1839.	4.1	24
32	Epicardial adipose tissue in obesity-related cardiac dysfunction. <i>Heart</i> , 2022, 108, 339-344.	2.9	22
33	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. <i>Scientific Reports</i> , 2021, 11, 10166.	3.3	14
34	What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?. <i>Cell Reports Medicine</i> , 2021, 2, 100284.	6.5	4
35	Weight Management in Adolescents with Polycystic Ovary Syndrome. <i>Current Obesity Reports</i> , 2021, 10, 311-321.	8.4	6
36	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	27.0	171
37	Association of metabolic bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174%772 participants. <i>Lancet, The</i> , 2021, 397, 1830-1841.	13.7	241
38	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. <i>Lancet, The</i> , 2021, 397, 1736-1748.	13.7	160
39	Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664. <i>British Journal of Diabetes</i> , 2021, 21, 120-122.	0.2	1
40	Microbial regulation of enteroendocrine cells. <i>Med</i> , 2021, 2, 553-570.	4.4	17
41	Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 2281-2298.	3.3	1

#	ARTICLE	IF	CITATIONS
42	Cut-brain communication and obesity: understanding functions of the vagus nerve. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	43
43	Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. <i>Advances in Nutrition</i> , 2021, 12, 2540-2552.	6.4	10
44	Obesity: Overview of Weight Management. <i>Endocrine Practice</i> , 2021, 27, 626-635.	2.1	13
45	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645507.	3.5	28
46	GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. <i>Diabetes</i> , 2021, 70, 1938-1944.	0.6	17
47	Adapting pediatric obesity care to better suit adolescent patients: Design of a treatment platform and results compared with standard care in the national patient quality register. <i>Obesity Science and Practice</i> , 2021, 7, 699-710.	1.9	5
48	Semaglutide for Weight Loss. <i>Annals of Pharmacotherapy</i> , 2022, 56, 224-226.	1.9	2
49	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss. <i>European Heart Journal</i> , 2021, 42, 2628-2629.	2.2	0
51	Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. <i>Diabetologia</i> , 2021, 64, 1963-1972.	6.3	73
53	The melanocortin pathway and energy homeostasis: From discovery to obesity therapy. <i>Molecular Metabolism</i> , 2021, 48, 101206.	6.5	114
54	Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021120.	3.7	10
55	Breaking New Ground with Incretin Therapy in Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 560-561.	27.0	10
56	The Weighty Issue of Treating Obesity in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
57	Heart failure management; a perspective from diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108849.	2.8	1
59	A 2021 Update on the Use of Liraglutide in the Modern Treatment of "Diabesity": A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 669.	2.0	14
60	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. <i>Frontiers in Endocrinology</i> , 2021, 12, 694284.	3.5	22
61	Clinical management and treatment of obesity in China. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 393-405.	11.4	105
63	Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2807-2827.	2.4	32

#	ARTICLE	IF	CITATIONS
64	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	1.0	13
65	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, , .	4.0	5
66	Un largo y pedregoso camino hacia el correcto tratamiento de la obesidad. <i>Medicina Clínica</i> , 2021, 157, 176-177.	0.6	0
67	Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD. <i>Frontiers in Physiology</i> , 2021, 12, 710285.	2.8	14
68	Letter to the Editor: Do Not Throw the Band Out with the Bath Water. <i>Obesity Surgery</i> , 2021, 31, 5476-5477.	2.1	1
69	Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 524-541.	0.8	5
70	Pharmacotherapy in Childhood Obesity. <i>Hormone Research in Paediatrics</i> , 2022, 95, 177-192.	1.8	9
71	Cardiovascular Safety and Superiority of Anti-Obesity Medications. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3199-3208.	2.4	7
72	Confirmatory psychometric evaluations of the Impact of Weight on Quality of Lifeâ€“Lite Clinical Trials Version (<scp>IWQOLâ€“Liteâ€“CT</scp>). <i>Clinical Obesity</i> , 2021, 11, e12477.	2.0	7
73	Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature. <i>Obesity Surgery</i> , 2021, 31, 4575-4584.	2.1	9
74	100 years of insulin: celebrating the past, present and future of diabetes therapy. <i>Nature Medicine</i> , 2021, 27, 1154-1164.	30.7	94
75	The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings. <i>Current Obesity Reports</i> , 2021, 10, 396-408.	8.4	20
76	Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 877-891.	4.1	7
77	Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). <i>Diabetes Therapy</i> , 2021, 12, 2133-2147.	2.5	20
79	Progress in Pharmacotherapy for Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 129.	7.4	42
80	Preoperative weight loss: a value-added opportunity?. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1853-1854.	1.2	0
81	Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1171-1188.	5.7	17
82	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021, 385, e4.	27.0	24

#	ARTICLE	IF	CITATIONS
83	A Practical Review of Diabetes Mellitus Type 2 Treatment in Primary Care. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2021, .	0.6	2
84	How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 2021, 10, R200-R212.	1.9	17
85	Pharmacotherapy of obesity: An update. Pharmacological Research, 2021, 169, 105649.	7.1	28
86	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	13.7	222
87	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Review of Clinical Pharmacology, 2021, 14, 1193-1204.	3.1	12
88	The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis, 2021, 330, 52-60.	0.8	23
89	Obesity as a Risk Factor for Severe COVID-19: Summary of the Best Evidence and Implications for Health Care. Current Obesity Reports, 2021, 10, 282-289.	8.4	41
90	Diets and drugs for weight loss and health in obesity – An update. Biomedicine and Pharmacotherapy, 2021, 140, 111789.	5.6	68
91	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	3.8	23
92	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes, Obesity and Metabolism, 2022, 24, 28-43.	4.4	40
93	Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. British Journal of Pharmacology, 2022, 179, 557-570.	5.4	46
94	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 29-38.	3.6	82
95	Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. International Journal of Obesity, 2022, 46, 21-29.	3.4	26
96	Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	8
98	Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. Diabetes Research and Clinical Practice, 2021, 178, 108935.	2.8	9
99	A long and stony road to the correct treatment of obesity. Medicina Clínica (English Edition), 2021, 157, 176-177.	0.2	0
100	Slow digestion-oriented dietary strategy to sustain the secretion of GLP-1 for improved glucose homeostasis. Comprehensive Reviews in Food Science and Food Safety, 2021, 20, 5173-5196.	11.7	14
101	Research in brief: Effective pharmacotherapy for the management of obesity. Clinical Medicine, 2021, 21, e517-e518.	1.9	3

#	ARTICLE	IF	CITATIONS
102	GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 3955.	2.4	7
103	Child and adolescent obesity. <i>Paediatrics and Child Health (United Kingdom)</i> , 2021, 31, 322-329.	0.4	2
104	Antiobesity drug therapy: An individualized and comprehensive approach. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 440-448.	1.3	9
106	Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 60.	4.8	3
107	Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding. <i>Journal of Physiology</i> , 2022, 600, 1053-1078.	2.9	15
108	A primer on obesity-related cardiomyopathy. <i>Physiological Reviews</i> , 2022, 102, 1-6.	28.8	9
109	Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum. <i>Journal of the American College of Cardiology</i> , 2021, 78, 453-464.	2.8	45
110	Closing the Glycemic Divide. <i>Journal of the American College of Cardiology</i> , 2021, 78, 465-467.	2.8	0
111	Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. <i>Journal of Hepatology</i> , 2021, 75, 1284-1291.	3.7	229
112	Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 518-521.	1.5	5
114	Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129917.	2.4	2
115	Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?. <i>Cardiovascular Research</i> , 2021, 117, e120-e122.	3.8	3
116	Future perspectives in diabetes treatment: Semaglutide, a glucagon-like peptide-1 receptor agonist (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1167.	1.8	7
117	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 869.	3.8	11
119	The evolving story of incretins (<sc>GIP</sc> and <sc>GLP</sc>-1) in metabolic and cardiovascular disease: A pathophysiological update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 5-29.	4.4	139
120	Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2021, 78, e38-e50.	2.7	79
121	Bariatric Surgery: It's Not Just Incretins!. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e883-e885.	3.6	1
122	“You Are Always at War With Yourself”-The Perceptions and Beliefs of People With Obesity Regarding Obesity as a Disease. <i>Qualitative Health Research</i> , 2021, 31, 2470-2485.	2.1	4

#	ARTICLE	IF	CITATIONS
123	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	8.6	244
124	IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. <i>EClinicalMedicine</i> , 2021, 39, 101088.	7.1	23
125	Oral Capsaicinoid Administration Alters the Plasma Endocannabinoidome and Fecal Microbiota of Reproductive-Aged Women Living with Overweight and Obesity. <i>Biomedicines</i> , 2021, 9, 1246.	3.2	7
126	New insights into bisphenols induced obesity in zebrafish ( <i>Danio rerio</i> ): Activation of cannabinoid receptor CB1. <i>Journal of Hazardous Materials</i> , 2021, 418, 126100.	12.4	35
127	Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. <i>Hepatology</i> , 2021, 74, 3472-3478.	7.3	21
128	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1150-1161.	3.7	79
129	Management of type 2 diabetes without insulin: An update for the PCP. <i>Disease-a-Month</i> , 2021, , 101290.	1.1	0
132	Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumb: What do They Mean for Clinical Practice?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021, 30, 196-208.	3.6	27
133	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1036-1046.	8.1	23
134	Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. <i>British Journal of Pharmacology</i> , 2022, 179, 600-624.	5.4	21
137	Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 30-39.	4.4	9
138	Obesity – An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. <i>Biomolecules</i> , 2021, 11, 1426.	4.0	35
139	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	6.3	128
140	Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity. <i>Frontiers in Endocrinology</i> , 2021, 12, 735019.	3.5	39
141	Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application. <i>Molecular Metabolism</i> , 2021, 51, 101237.	6.5	27
142	Comment on: The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, e33-e34.	1.2	0
143	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	3.0	9
144	Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 40-52.	4.4	17



#	ARTICLE	IF	CITATIONS
145	Metreleptin treatment of non-HIV lipodystrophy syndromes. <i>Presse Medicale</i> , 2021, 50, 104070.	1.9	5
146	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 747-756.	2.2	2
147	The Treatment of Obesity in Cardiac Rehabilitation. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2021, 41, 295-301.	2.1	18
148	Metabolic syndrome, rheumatoid and psoriatic arthritis: Managing cardiovascular risk. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1103-1105.	1.9	5
149	Pharmacologic Weight Loss for Heart Failure With Preserved Ejection Fraction: Getting to the Core of the Problem. <i>Circulation: Heart Failure</i> , 2021, 14, e008554.	3.9	0
150	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113888.	13.7	62
151	Obesity and long-term outcomes after incident stroke: a prospective population-based cohort study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 2111-2121.	7.3	17
152	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. <i>International Journal of Cardiology</i> , 2021, 338, 248-257.	1.7	1
153	Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. <i>Journal of Pediatrics</i> , 2021, 236, 137-147.e13.	1.8	42
154	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 97-98.	3.1	6
155	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 94-105.	4.4	34
156	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. <i>Lancet</i> , 2022, 399, 394-405.	13.7	215
157	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 595-605.	11.4	61
158	Les nouvelles thérapeutiques du diabète. <i>La Presse Médicale Formation</i> , 2021, 2, 574-574.	0.1	0
159	A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing. <i>Molecular Metabolism</i> , 2021, 53, 101240.	6.5	41
160	Recent advances in peptide-based therapy for Type 2 diabetes and obesity. <i>Peptides</i> , 2021, 145, 170652.	2.4	2
161	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100250.	3.0	51
162	Gibt es eine Abkürzung zum Wunschgewicht?. , 2021, , 173-176.		0

#	ARTICLE	IF	CITATIONS
163	Obesity-Related Glomerulopathy: Clinical Management. <i>Seminars in Nephrology</i> , 2021, 41, 358-370.	1.6	6
165	Assessment of Atrial Fibrosis and Its Implications in Atrial Fibrillation and Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	1
166	Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	16
167	GLP-1 physiology informs the pharmacotherapy of obesity. <i>Molecular Metabolism</i> , 2022, 57, 101351.	6.5	119
169	Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. <i>Molecular Metabolism</i> , 2021, 54, 101352.	6.5	18
170	Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention?. <i>Circulation</i> , 2021, 144, 1359-1361.	1.6	6
171	Oxytocin as an Anti-obesity Treatment. <i>Frontiers in Neuroscience</i> , 2021, 15, 743546.	2.8	12
172	Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity?. <i>Frontiers in Endocrinology</i> , 2021, 12, 737686.	3.5	6
173	Understanding the pathophysiologic pathways that underlie obesity and options for treatment. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 321-338.	2.4	8
175	Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2022, 43, 507-557.	20.1	39
176	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	10.7	394
177	Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment. <i>Årno-Rossijskij Årurnal TerapevtiÄeskoj Praktiki</i> , 2021, 2, 18-29.	0.3	2
178	Treating the Chronic Disease of Obesity. <i>Medical Clinics of North America</i> , 2021, 105, 983-1016.	2.5	15
179	A novel intragastric balloon for treatment of obesity and type 2 diabetes. A two-center pilot trial. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 232-238.	1.5	1
180	Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2991-3000.	3.0	16
181	Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. <i>Journal of Investigative Medicine</i> , 2022, 70, 5-13.	1.6	48
182	High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. <i>Annals of Pharmacotherapy</i> , 2022, 56, 941-950.	1.9	7
183	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e022930.	3.7	10

#	ARTICLE	IF	CITATIONS
184	Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?. ACS Pharmacology and Translational Science, 2021, 4, 1747-1770.	4.9	31
185	A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors. Neuroscience and Biobehavioral Reviews, 2021, 131, 1169-1179.	6.1	10
186	Body Weight Change and Cardiovascular Disease: Effect of Weight Gain, Weight Loss, and Weight Cycling. Cardiovascular Prevention and Pharmacotherapy, 2021, 3, 73-81.	0.1	1
187	Weight, shape, and body composition changes at menopause. Journal of Mid-Life Health, 2021, 12, 187.	0.6	10
188	Is it time to reconsider the treatment paradigm for obese patients with hypertension?. Journal of Human Hypertension, 2021, , .	2.2	3
189	Health state utilities associated with weight loss in type 2 diabetes and obesity. Journal of Medical Economics, 2022, 25, 14-25.	2.1	3
190	Childhood obesity: A review of current and future management options. Clinical Endocrinology, 2022, 96, 288-301.	2.4	26
191	The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon. Life Sciences, 2022, 288, 120188.	4.3	13
192	Vasodilator Dysfunction in Human Obesity. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	1
193	Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Molecular Metabolism, 2022, 55, 101407.	6.5	24
196	Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications. Endocrine Practice, 2022, 28, 214-222.	2.1	19
197	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 918-932.	4.1	41
198	Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet, The, 2021, 398, 1965-1973.	13.7	43
199	Efglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 2105-2107.	27.0	2
200	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International Journal of Obesity, 2022, 46, 555-563.	3.4	16
201	Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obesity Facts, 2022, 15, 83-89.	3.4	18
202	Plaque progression: Where, why, and how fast? A review of what we have learned from the analysis of patient data from the PARADIGM registry. Journal of Cardiovascular Computed Tomography, 2022, 16, 294-302.	1.3	3
203	Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women. Frontiers in Endocrinology, 2021, 12, 742873.	3.5	11

#	ARTICLE	IF	CITATIONS
204	Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. <i>Scientific Reports</i> , 2021, 11, 22521.	3.3	27
205	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2160-2172.	13.7	74
206	Anti-obesity drug discovery: advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 201-223.	46.4	357
207	Long-acting amylin analogue for weight reduction. <i>Lancet, The</i> , 2021, 398, 2132-2134.	13.7	6
209	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. <i>Postgraduate Medicine</i> , 2022, 134, 14-19.	2.0	46
210	Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study. <i>Obesity Science and Practice</i> , 2022, 8, 320-327.	1.9	10
211	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	3.5	15
212	Obesity in cystic fibrosis. <i>Journal of Clinical and Translational Endocrinology</i> , 2021, 26, 100276.	1.4	13
213	Antiobesity drug therapy. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 657.1-657.	1.3	0
214	Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2021, 42, 101213.	7.1	41
215	Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review. <i>Peptides</i> , 2022, 147, 170706.	2.4	7
216	Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 55-84.	9.4	24
217	The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. <i>Current Cardiology Reports</i> , 2022, , .	2.9	1
218	Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. <i>Endocrine</i> , 2022, 75, 718-724.	2.3	26
219	The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 15-27.	4.4	24
220	Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 138.	7.4	293
221	Editorial: Obesity, metabolic phenotypes and COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 155121.	3.4	20
222	Drugs for Treating Obesity. <i>Handbook of Experimental Pharmacology</i> , 2021, , 387-414.	1.8	12

#	ARTICLE	IF	CITATIONS
223	Glucagon-Like Peptide-1 Receptor Agonistsâ€™ Use in Clinical Practice. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 328-336.	1.4	5
225	Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2022, 399, 259-269.	13.7	156
226	SÃndrome metabÃ³lico: revisiÃ³n de la literatura. <i>Medicina Y Laboratorio</i> , 2022, 26, 47-62.	0.1	4
227	Editorial: Conference on â€œObesity and the Brainâ€™. <i>Proceedings of the Nutrition Society</i> , 2022, , 1-6.	1.0	0
228	Efficacy and safety of epeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002207.	2.8	5
229	Cortical Bone Loss Following Gastric Bypass Surgery Is Not Primarily Endocortical. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 753-763.	2.8	0
230	Dieting. , 2023, , 662-668.		0
231	Sudden Cardiac Death in Diabetes and Obesity: Mechanisms and Therapeutic Strategies. <i>Canadian Journal of Cardiology</i> , 2022, 38, 418-426.	1.7	18
234	Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 155-163.	2.4	9
235	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	8.1	92
236	Is polypharmacy the future for pharmacological management of obesity?. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, 23, 100322.	1.4	5
237	Gastrointestinal Interoception in Eating Disorders: Charting a New Path. <i>Current Psychiatry Reports</i> , 2022, 24, 47-60.	4.5	28
238	Semaglutide for Weight Loss: Was It Worth the Weight?. <i>Cardiology in Review</i> , 2022, 30, 324-329.	1.4	5
239	OUP accepted manuscript. <i>British Journal of Surgery</i> , 2022, , .	0.3	1
240	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. <i>European Heart Journal</i> , 2022, 43, 263-270.	2.2	7
243	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
245	Obesity: Treatments, Conceptualizations, and Future Directions for a Growing Problem. <i>Biology</i> , 2022, 11, 160.	2.8	6
246	Metrics matter: Toward consensus reporting of BMI and weightâ€™related outcomes in pediatric obesity clinical trials. <i>Obesity</i> , 2022, 30, 571-572.	3.0	11

#	ARTICLE	IF	CITATIONS
247	European Society of Cardiology: cardiovascular disease statistics 2021. <i>European Heart Journal</i> , 2022, 43, 716-799.	2.2	343
248	Long-acting amylin analogues for the management of obesity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 183-190.	2.3	15
249	Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect. <i>Scientific Reports</i> , 2022, 12, 1696.	3.3	2
250	GLP-1RAs for the treatment of obesity in women after menopause. <i>Maturitas</i> , 2022, 156, 65-66.	2.4	1
251	New developments in the prospects for GLP-1 therapy. <i>British Journal of Pharmacology</i> , 2022, 179, 489-491.	5.4	7
252	Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2022, 43, 1955-1969.	2.2	90
253	Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 193-206.	11.4	90
254	Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia. <i>Lancet Diabetes and Endocrinology</i> , 2022, , .	11.4	0
255	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 281-295.	2.4	35
256	Comment on: The Impact of Bariatric Surgery on the Risk of Coronary Revascularization. <i>œA Bariatric Surgery Randomized Control Trial for Major Adverse Cardiovascular Events. Are we running out of time?œ. <i>Surgery for Obesity and Related Diseases</i>, 2022, , .</i>	1.2	0
257	NICE recommends weight loss drug semaglutide for obese adults. <i>BMJ, The</i> , 2022, 376, o340.	6.0	4
258	Growth differentiation factor 15 (<sc>GDF15</sc>) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1010-1020.	4.4	14
259	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. <i>JAMA Health Forum</i> , 2021, 2, e214182.	2.2	58
260	Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity. <i>Journal of Investigative Medicine</i> , 2022, 70, 3-4.	1.6	5
261	New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1339-e1347.	3.6	33
262	Evidence Base for Bariatric Surgery. , 2022, , 1-23.		0
263	An integrated platform approach enables discovery of potent, selective and ligand-competitive cyclic peptides targeting the GIP receptor. <i>Chemical Science</i> , 2022, 13, 3256-3262.	7.4	4
265	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. <i>Frontiers in Physiology</i> , 2021, 12, 785879.	2.8	3

#	ARTICLE	IF	CITATIONS
266	Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. <i>Nature Communications</i> , 2022, 13, 1057.	12.8	46
267	Camptothecin effectively treats obesity in mice through GDF15 induction. <i>PLoS Biology</i> , 2022, 20, e3001517.	5.6	18
268	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. <i>Frontiers of Medicine</i> , 2022, 16, 17-24.	3.4	2
269	The future of bariatric surgery research: A worldwide mapping of registered trials. <i>Obesity Reviews</i> , 2022, 23, e13433.	6.5	5
270	Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus: a systematic review and meta-analysis of randomized control trials. <i>Obesity Reviews</i> , 2022, 23, e13435.	6.5	53
271	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. <i>Current Diabetes Reports</i> , 2022, 22, 129-136.	4.2	5
272	Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. <i>Current Opinion in Cardiology</i> , 2022, Publish Ahead of Print, .	1.8	3
273	Protocol for the IMPACT Trial: Improving Healthcare Outcomes in American Transplant Recipients Using Culturally-Tailored Novel Technology. , 2022, 32, e1-e12.		4
274	Increasing Motivation for Lifestyle Change Is Not Enough to Treat Obesity. <i>Annals of Internal Medicine</i> , 2022, , .	3.9	1
276	Body weight, diabetes incidence vascular events and survival 15 years after very low calorie diet in community medical clinics in the UK. <i>BMJ Nutrition, Prevention and Health</i> , 2022, 5, 55-61.	3.7	1
277	Integrating High-Dose GLP-1 Receptor Agonists Into the Care of People With or at Risk for Type 2 Diabetes. <i>ADCES in Practice</i> , 0, , 2633559X2210862.	0.2	0
278	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 359-375.	2.0	22
279	Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. <i>Obesity</i> , 2022, 30, 841-857.	3.0	25
280	The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 28-36.	3.6	15
281	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2021. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
283	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 838410.	3.5	42
284	LKB1 acts as a critical brake for the glucagon-mediated fasting response. <i>Hepatology Communications</i> , 2022, 6, 1949-1961.	4.3	4
285	Implementation of Cardiometabolic Centers and Training Programs. <i>Current Diabetes Reports</i> , 2022, , 1.	4.2	0

#	ARTICLE	IF	CITATIONS
286	Weight Loss Outcomes With Telemedicine During COVID-19. <i>Frontiers in Endocrinology</i> , 2022, 13, 793290.	3.5	6
287	Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 165-180.	4.7	10
288	Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?. <i>JAMA Internal Medicine</i> , 2022, 182, 520.	5.1	2
289	Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. <i>Obesity</i> , 2022, 30, 802-840.	3.0	41
290	Trends in the Utilization of Intra-gastric Balloons: a 5-Year Analysis of the MBSAQIP Registry. <i>Obesity Surgery</i> , 2022, 32, 1649-1657.	2.1	4
291	Leveraging GPCR signaling in thermogenic fat to counteract metabolic diseases. <i>Molecular Metabolism</i> , 2022, 60, 101474.	6.5	2
292	Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 944-959.	3.7	17
294	Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review. <i>Obesity Reviews</i> , 2022, 23, e13448.	6.5	42
295	Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3451.	4.1	14
296	A Nomogram for Predicting Non-Response to Surgery One Year after Elective Total Hip Replacement. <i>Journal of Clinical Medicine</i> , 2022, 11, 1649.	2.4	1
297	Historical and cultural aspects of obesity: From a symbol of wealth and prosperity to the epidemic of the 21st century. <i>Obesity Reviews</i> , 2022, 23, e13440.	6.5	12
299	Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss. <i>Journal of General Internal Medicine</i> , 2022, , 1.	2.6	0
300	Beneficial Metabolic Effects of Praliguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model. <i>Frontiers in Pharmacology</i> , 2022, 13, 852080.	3.5	2
301	The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2022, 79, 138-139.	0.4	0
302	Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. <i>JAMA Internal Medicine</i> , 2022, 182, 513.	5.1	51
303	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	2.4	9
304	The Impact of Obesity on Sudden Cardiac Death Risk. <i>Current Cardiology Reports</i> , 2022, 24, 497-504.	2.9	7
306	Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo. <i>Jacs Au</i> , 2022, 2, 1007-1017.	7.9	6



#	ARTICLE	IF	CITATIONS
307	Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. <i>Atherosclerosis</i> , 2022, 352, 88-95.	0.8	13
308	Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1676-1680.	4.4	7
309	Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure. <i>Heart Failure Reviews</i> , 2023, 28, 47-61.	3.9	9
310	Obesity-related glomerulopathy: Current approaches and future perspectives. <i>Obesity Reviews</i> , 2022, 23, e13450.	6.5	26
311	GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102189.	3.5	10
312	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
313	Comparing effects of obesity treatment with very low energy diet and bariatric surgery after 2 years: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e053242.	1.9	3
314	Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis. <i>Current Problems in Cardiology</i> , 2023, 48, 101194.	2.4	5
315	Novel drugs in pharmacotherapy of obesity. <i>PraktickÃ© LÃ©kÃ¡renstvÃ¡</i> , 2021, 17, 74-80.	0.1	0
316	Obesity Management in Kidney Transplant Candidates: Current Paradigms and Gaps in Knowledge. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 528-541.	1.4	4
317	Obesity, Inflammation, and Severe Asthma: an Update. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 46.	5.3	29
318	Semaglutide for the treatment of obesity. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 159-166.	4.9	26
320	Adding liraglutide to diet and exercise to maintain weight loss – is it worth it?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 447-451.	1.8	0
321	Reagents and models for detecting endogenous GLP1R and GIPR. <i>EBioMedicine</i> , 2021, 74, 103739.	6.1	12
322	Pharmacotherapy of obesity in complex diseases. <i>Clinical Obesity</i> , 2022, 12, e12497.	2.0	6
323	Estimands – a basic element for clinical trials. Part 29 of a series on evaluation of scientific publications. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, , .	0.9	2
324	Clinical review of subcutaneous semaglutide for obesity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 184-193.	1.5	12
325	Obesity and GLP-1 RAs. <i>Journal of Investigative Medicine</i> , 2022, 70, 1-2.	1.6	1

#	ARTICLE	IF	CITATIONS
326	Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. <i>Hepatology Communications</i> , 2022, 6, 1250-1261.	4.3	3
327	Once-a-week semaglutide for obesity or overweight: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 722-726.	4.4	6
328	The emerging role of incretins and twincretins. <i>Nature Reviews Endocrinology</i> , 2022, 18, 73-74.	9.6	6
330	Eating and nutrition links to cancer. , 2022, , 225-252.		0
331	Targeting the Enteroendocrine System for Treatment of Obesity. <i>Handbook of Experimental Pharmacology</i> , 2022, , 1.	1.8	0
332	Effect of Bariatric Surgery on Risk of Complications After Total Knee Arthroplasty. <i>JAMA Network Open</i> , 2022, 5, e226722.	5.9	38
333	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV0000000000000153.	2.4	167
334	Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1492-1505.	2.8	32
335	A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus. <i>Appetite</i> , 2022, 174, 106022.	3.7	11
336	Semaglutide: a game changer for metabolic diseases?. <i>Exploration of Medicine</i> , 0, , 173-180.	1.5	1
337	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <sc>STEP</sc> 1 trial extension. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1553-1564.	4.4	151
338	The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101922.	1.5	12
339	Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100018.		13
340	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. <i>Journal of Hepatology</i> , 2022, 77, 607-618.	3.7	79
341	When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14742.	6.9	14
342	Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study. , 2022, 2, 100016.		2
343	Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. <i>American Journal of Human Genetics</i> , 2022, 109, 767-782.	6.2	101
344	Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 131.	17.1	190

#	ARTICLE	IF	CITATIONS
345	Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2022, 12, 6666.	3.3	17
346	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-17.	3.1	5
347	Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2154-2166.	3.6	10
348	Semaglutide for weight loss. <i>Canadian Family Physician</i> , 2021, 67, 842-842.	0.4	3
350	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. <i>Cardiovascular Diabetology</i> , 2022, 21, 63.	6.8	19
352	Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 761-775.	10.7	204
355	Optimizing pre-donation physiologic evaluation for enhanced recovery after living liver donation – Systematic review and multidisciplinary expert panel recommendations. <i>Clinical Transplantation</i> , 2022, , e14680.	1.6	2
356	Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1053-1057.	1.2	3
357	Intensive management of obesity in people with Prader-Willi syndrome. <i>Endocrine</i> , 2022, 77, 57-62.	2.3	4
358	Menopause: a cardiometabolic transition. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 442-456.	11.4	64
359	Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	4
360	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 2452-2467.	2.9	58
361	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	2.1	323
362	NAMS 2021 Utian Translational Science Symposium September 2021, Washington, DC Charting the path to health in midlife and beyond: the biology and practice of wellness. <i>Menopause</i> , 2022, 29, 504-513.	2.0	0
363	The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion. <i>Metabolites</i> , 2022, 12, 420.	2.9	16
364	Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China. <i>European Journal of Health Economics</i> , 2022, , 1.	2.8	1
365	Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. <i>Fertility and Sterility</i> , 2022, 117, 924-935.	1.0	34
366	Obesity treatment - overview of pharmacological and surgical methods. <i>Journal of Education, Health and Sport</i> , 2022, 12, 40-48.	0.1	1

#	ARTICLE	IF	CITATIONS
367	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends in Endocrinology and Metabolism, 2022, 33, 424-442.	7.1	23
368	Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review. European Journal of Medicinal Chemistry, 2022, 237, 114405.	5.5	13
370	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiologica, 2023, 78, 552-564.	0.9	2
371	Top studies of 2021 relevant to primary care. Canadian Family Physician, 2022, 68, 329-333.	0.4	2
373	Comparison of the Efficacy and Safety of the FDA-approved Intra-gastric Balloon Systems in a Clinical Setting. Journal of Clinical Gastroenterology, 2023, 57, 578-585.	2.2	2
374	Obesity, weight loss and gynecologic neoplasms: a narrative review. Women and Health, 0, , 1-12.	1.0	0
375	Regulation of body weight: Lessons learned from bariatric surgery. Molecular Metabolism, 2023, 68, 101517.	6.5	17
376	Once-Weekly Semaglutide for Weight Management: A Clinical Review. Journal of Pharmacy Technology, 2022, 38, 239-246.	1.0	3
377	Sleeve Gastrectomy Improves High-Fat Diet-Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats. Journal of Gastrointestinal Surgery, 2022, 26, 1607-1618.	1.7	0
378	Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Current Atherosclerosis Reports, 2022, 24, 643-654.	4.8	13
380	Discovery of the GI Effects of GLP-1: An Historical Perspective. Digestive Diseases and Sciences, 2022, 67, 2716-2720.	2.3	5
381	Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity. American Journal of Cardiology, 2022, 175, 182-184.	1.6	3
383	The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients, 2022, 14, 2217.	4.1	8
384	Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2. Journal of Clinical and Translational Hepatology, 2022, 10, 965-971.	1.4	2
387	Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharmaceutical Research, 2022, 39, 1233-1248.	3.5	31
388	Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International, 2022, 102, 248-260.	5.2	112
389	The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts. Neurology, 2022, 99, 267-268.	1.1	6
390	Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022, 387, 205-216.	27.0	799

#	ARTICLE	IF	CITATIONS
391	Total Diet Replacement Within an Integrated Intensive Lifestyle Intervention for Remission of Type 2 Diabetes: Lessons From DiRECT. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	5
392	GLP-1 analogues in clinical management of obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100360.	1.4	3
393	SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy. <i>Acta Diabetologica</i> , 0, , .	2.5	0
395	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 171-179.	1.9	4
396	Modifying insulin to improve performance. <i>Science</i> , 2022, 376, 1270-1271.	12.6	2
397	Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. <i>Postgraduate Medicine</i> , 0, , 1-5.	2.0	0
398	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. <i>Diabetes Care</i> , 2022, 45, 2396-2405.	8.6	19
399	Clinical practice guidelines update 2022: Focus on diabetes. <i>Pharmacy Today</i> , 2022, 28, 54-62.	0.0	0
400	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
401	Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 852-859.	2.1	9
402	Gut hormones and reproduction (Hormones intestinalis et reproduction). <i>Annales D'Endocrinologie</i> , 2022, , .	1.4	3
404	Medical Weight Management: A Multidisciplinary Approach. , 0, , .		0
405	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211080.	2.5	10
406	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. , 2022, 18, 43.		4
407	Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?., 2022, 18, 35.		5
408	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	1.4	0
410	Appetite Control Mechanisms and Obesity. <i>Journal of Korean Diabetes</i> , 2022, 23, 89-96.	0.3	0
411	Recent Advances in Anti-Obesity Drugs. <i>Journal of Korean Diabetes</i> , 2022, 23, 113-127.	0.3	2

#	ARTICLE	IF	CITATIONS
412	Patient insights into the experience of trying to achieve weight-loss and future expectations upon commencement of a primary care-led weight management intervention: A qualitative, baseline exploration. PLoS ONE, 2022, 17, e0270426.	2.5	3
413	The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes. Annals of Pharmacotherapy, 0, , 106002802211073.	1.9	0
414	Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 7499.	4.1	28
415	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	1.2	5
416	Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 0, 13, .	3.5	19
417	Ease of use and acceptability of the novel semaglutide 2.4 mg single-dose peninjector in people with overweight or obesity in the <sc>STEP</sc> 8 phase <sc>III</sc> trial. Diabetes, Obesity and Metabolism, 2022, 24, 2273-2276.	4.4	2
418	COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave. Current Atherosclerosis Reports, 2022, 24, 607-617.	4.8	4
419	Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. Biomedicines, 2022, 10, 1661.	3.2	5
420	Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular Metabolism, 2022, 63, 101533.	6.5	43
421	Leveraging the Microbiome for Obesity: Moving From Form to Function. Frontiers in Endocrinology, 0, 13, .	3.5	0
422	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases, 2022, 10, 6759-6768.	0.8	3
423	Highlights in ASCVD Primary Prevention for 2021. Journal of the American Heart Association, 2022, 11, .	3.7	3
424	Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Research and Clinical Practice, 2022, 190, 109980.	2.8	20
425	Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice. Biochemical and Biophysical Research Communications, 2022, 622, 22-29.	2.1	4
426	Predictors and determinants of albuminuria in people with prediabetes and diabetes based on smoking status: A cross-sectional study using the UK Biobank data. EClinicalMedicine, 2022, 51, 101544.	7.1	4
427	Obesity pillars roundtable: Phentermine – Past, present, and future. , 2022, 3, 100024.		5
428	A purinergic call to arms from dying brown adipocytes. Cell Stress, 2022, 6, 68-71.	3.2	0
429	Obesity and Endothelial Function. Biomedicines, 2022, 10, 1745.	3.2	19

#	ARTICLE	IF	CITATIONS
430	<scp>Glucagon-like peptide</scp>-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor polyagonists: a new era in obesity pharmacotherapy. <i>Obesity</i> , 2022, 30, 1718-1721.	3.0	4
431	A narrative review of anti-obesity medications for obese patients with osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1381-1395.	1.8	4
432	Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects. <i>European Heart Journal</i> , 0, , .	2.2	2
433	A qualitative study to examine meaningful change in physical function associated with weight-loss. <i>Quality of Life Research</i> , 0, , .	3.1	1
434	The effect of bariatric surgery in comparison with the control group on the prevention of comorbidities in people with severe obesity: a prospective cohort study. <i>BMC Surgery</i> , 2022, 22, .	1.3	6
435	Anti-obesity weight loss medications: Short-term and long-term use. <i>Life Sciences</i> , 2022, 306, 120825.	4.3	5
436	The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211124.	3.2	9
437	Pharmacologic treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 408-416.	0.3	0
438	Insulin sensitive human adipocytes for in vitro studies. <i>Nature Reviews Endocrinology</i> , 2022, 18, 591-592.	9.6	1
439	Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding. <i>Nature Metabolism</i> , 2022, 4, 836-847.	11.9	32
440	The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. <i>Obesity Surgery</i> , 2022, 32, 3280-3288.	2.1	23
441	European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline. <i>Clinical Nutrition</i> , 2022, , .	5.0	22
442	Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2218-2237.	1.8	58
443	Semaglutide for the treatment of obesity. <i>Journal of Education, Health and Sport</i> , 2022, 12, 1111-1123.	0.1	0
444	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4051.	3.7	11
445	Pharmacotherapy in obesity: the current state and the near future. <i>Journal of the Korean Medical Association</i> , 2022, 65, 514-531.	0.3	0
446	Revisional Surgery or Pharmacotherapy for Insufficient Weight Loss and Weight Regain After Primary Bariatric Procedure: a Descriptive Study. <i>Obesity Surgery</i> , 2022, 32, 3298-3304.	2.1	7
447	Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	9

#	ARTICLE	IF	CITATIONS
448	Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	7
449	Pharmacologic Weight Management in the Era of Adolescent Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2716-2728.	3.6	6
450	The Related Metabolic Diseases and Treatments of Obesity. <i>Healthcare (Switzerland)</i> , 2022, 10, 1616.	2.0	28
451	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	2.1	146
452	Derivatization with fatty acids in peptide and protein drug discovery. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 59-80.	46.4	19
454	Weight loss with glucagonâ€like peptideâ€1 receptor agonists in <scp>Bardetâ€Biedl</scp> syndrome. <i>Clinical Obesity</i> , 2022, 12, .	2.0	5
455	Associations between obesity parameters and the risk of incident atrial fibrillation and ischaemic stroke in the different age groups. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
456	Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans. <i>ELife</i> , 0, 11, .	6.0	6
457	Carbamazepine Therapy After Bariatric Surgery: Eight Sleeve Gastrectomy Cases and Review of the Literature. <i>Obesity Surgery</i> , 2022, 32, 3481-3486.	2.1	4
460	Combination antiâ€obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center. <i>Obesity Science and Practice</i> , 2023, 9, 203-209.	1.9	5
461	Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer. <i>Cancer Discovery</i> , 2022, 12, 2258-2279.	9.4	18
462	Antipsychoticâ€induced weight gain: Is the weight over? New guidelines needed. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 185-189.	4.5	1
463	Use of primary bariatric surgery among patients with obesity and diabetes. Insights from the Diabetes Collaborative Registry. <i>International Journal of Obesity</i> , 2022, 46, 2163-2167.	3.4	3
464	The role of GLP-1 receptor agonists in managing type 2 diabetes. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 457-464.	1.3	8
465	Gastrointestinal adverse events of semaglutide in patients with overweight or obesity. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	1
466	Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. <i>Annals of Hepatology</i> , 2023, 28, 100751.	1.5	2
467	European guideline on obesity care in patients with gastrointestinal and liver diseases â€“ Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. <i>United European Gastroenterology Journal</i> , 2022, 10, 663-720.	3.8	18
468	Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review. <i>Clinical Pharmacology: Advances and Applications</i> , 0, Volume 14, 61-67.	1.2	3



#	ARTICLE	IF	CITATIONS
469	Reframing the need for exercise therapy in the clinical management of people living with obesity. <i>Clinical Obesity</i> , 2022, 12, .	2.0	0
470	Weight response to GLP-1 receptor agonists: Why women do it better?. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108310.	2.3	1
471	The Role of Primary Care in Bariatric Surgery. , 2022, , 1-14.		0
472	Secretion and Impact of Gut Hormones in Obesity and Diabetes. , 2022, , .		0
473	Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review. <i>Cardiometabolic Syndrome Journal</i> , 2022, 2, 108.	0.6	1
474	The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. <i>Obesity Research and Clinical Practice</i> , 2022, 16, 353-363.	1.8	14
475	GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 867-884.	4.8	23
476	Signaling pathways in obesity: mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	72
477	Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitusâ€”From Prevalence to Diagnostic Approach and Treatment Strategies. <i>Journal of Clinical Medicine</i> , 2022, 11, 5144.	2.4	8
479	Glucagon-like peptide-1 analogues for overweight or obese adults. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
480	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2022, 65, 1925-1966.	6.3	273
481	Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies. <i>Journal of Cardiovascular Translational Research</i> , 0, , .	2.4	2
482	The potential of glucagon-like peptide-1 receptor agonists in heart failure. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
483	Impact of refitted <sc>raceâ€free eGFR</sc> formula on obesity pharmacotherapy options. <i>Obesity</i> , 2022, 30, 2204-2212.	3.0	2
484	Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. <i>JAMA Network Open</i> , 2022, 5, e2231982.	5.9	49
485	Semaglutide (GLPâ€1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. <i>Cell Biochemistry and Function</i> , 2022, 40, 903-913.	2.9	9
486	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2022, 45, 2753-2786.	8.6	435
487	Obesity in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, .	4.5	5

#	ARTICLE	IF	CITATIONS
488	A new era in gut hormone-based pharmacotherapy for people with obesity. Proceedings of the Nutrition Society, 2022, 81, 217-226.	1.0	5
489	Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 2022, 15, 1119-1125.	3.1	4
490	Semaglutida en enfermedad renal diab�tica: Experiencia en dos programas de salud renal en Colombia. Revista Colombiana De Endocrinolog�a, Diabetes & Metabolismo, 2022, 9, .	0.0	0
491	Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. Cardiovascular Diabetology, 2022, 21, .	6.8	4
492	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines, 2022, 10, 2274.	3.2	22
493	Worth the wait? Preconception weight reduction in women and men with obesity and infertility: a narrative review. Fertility and Sterility, 2022, 118, 447-455.	1.0	9
494	The Chemerin Receptor CMKLR1 Requires Full�Length Chemerin for High Affinity in Contrast to GPR1 as Demonstrated by a New Nanoluciferase�Based Binding Assay. ChemMedChem, 2022, 17, .	3.2	3
495	Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovascular Diabetology, 2022, 21, .	6.8	12
497	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 0, 13, .	3.5	15
498	Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes, 2022, 71, 2513-2529.	0.6	8
499	Effects of a novel weight�loss combination product containing orlistat and acarbose on obesity: A randomized, placebo�controlled trial. Obesity, 2022, 30, 2222-2232.	3.0	7
500	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. Obesity Medicine, 2022, 35, 100456.	0.9	8
501	Addressing insurance�related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery. Obesity, 2022, 30, 2338-2339.	3.0	4
502	Obesity and diabetes in people of African ancestry with <sc>HIV</sc>. HIV Medicine, 2023, 24, 380-388.	2.2	2
503	Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United�States. Journal of the American Heart Association, 2022, 11, .	3.7	4
504	Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile. Journal of Investigative Medicine, 2023, 71, 11-16.	1.6	4
505	Evaluation of a pharmacist�s impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting. Family Practice, 2023, 40, 255-260.	1.9	1
506	Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <sc>STEP</sc> 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism, 2023, 25, 468-478.	4.4	23

#	ARTICLE	IF	CITATIONS
507	A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods. <i>Contemporary Clinical Trials</i> , 2022, 122, 106909.	1.8	4
508	Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. <i>Physiology and Behavior</i> , 2022, 257, 113967.	2.1	8
509	Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. <i>EClinicalMedicine</i> , 2022, 54, 101691.	7.1	23
511	Adipose in Candyland: Diet and exercise in a pill. <i>Independent Nurse</i> , 2022, 2022, 24-26.	0.1	0
512	Semaglutide in Overweight and Obese patients: Cardiovascular and/or Renal Metabolic Benefits. <i>Revista Colombiana De Nefrología</i> , 2022, 9, .	0.1	0
513	Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review. <i>Andrology</i> , 2023, 11, 225-233.	3.5	5
514	Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. <i>Biomedicines</i> , 2022, 10, 2586.	3.2	6
515	The efficacy of goal-directed recommendations in overcoming barriers to elective ventral hernia repair in older adults. <i>Surgery</i> , 2023, 173, 732-738.	1.9	2
516	Alterations in Fecal Short-Chain Fatty Acids after Bariatric Surgery: Relationship with Dietary Intake and Weight Loss. <i>Nutrients</i> , 2022, 14, 4243.	4.1	8
517	Endosomal trafficking in metabolic homeostasis and diseases. <i>Nature Reviews Endocrinology</i> , 2023, 19, 28-45.	9.6	6
518	Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12305.	4.1	19
519	Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in <i>Caenorhabditis elegans</i> : A systematic review and meta-analysis. <i>Aging Cell</i> , 2022, 21, .	6.7	5
522	Obesity as a risk factor for cardiac arrhythmias. , 2022, 1, e000308.		4
523	LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. <i>Lancet</i> , The, 2022, 400, 1869-1881.	13.7	78
525	Obesity-Related Genes Expression in Testes and Sperm Parameters Respond to GLP-1 and Caloric Restriction. <i>Biomedicines</i> , 2022, 10, 2609.	3.2	0
527	Tirzepatide Once Weekly for the Treatment of Obesity. <i>New England Journal of Medicine</i> , 2022, 387, 1433-1435.	27.0	5
528	Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	21
529	Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. <i>Nature Medicine</i> , 2022, 28, 2083-2091.	30.7	137

#	ARTICLE	IF	CITATIONS
530	Semaglutide for the treatment of overweight and obesity: A review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 18-35.	4.4	26
531	Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs). , 2022, 4, 100039.		6
532	Endpoints and estimands: understanding trials of weight-loss drugs. <i>Nature Medicine</i> , 2022, 28, 2005-2006.	30.7	0
534	New research on treating obesity through medical and behavioural intervention. <i>Journal of Prescribing Practice</i> , 2022, 4, 424-425.	0.1	0
535	GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	15
536	Treating inflammation to combat non-alcoholic fatty liver disease. <i>Journal of Endocrinology</i> , 2023, 256, .	2.6	21
537	Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. <i>Obesity</i> , 2022, 30, 2111-2121.	3.0	12
538	Endobariatrics: well past infancy and maturing rapidly. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 592-599.	2.3	0
539	Dietary restriction and medical therapy drives PPAR $\alpha$ -regulated improvements in early diabetic kidney disease in male rats. <i>Clinical Science</i> , 2022, 136, 1485-1511.	4.3	4
540	Once-Weekly Semaglutide in Adolescents with Obesity. <i>New England Journal of Medicine</i> , 2022, 387, 2245-2257.	27.0	142
541	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. <i>Gastroenterology</i> , 2022, 163, 1198-1225.	1.3	39
542	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. <i>Biochemical Pharmacology</i> , 2022, 206, 115304.	4.4	5
543	The treatment of diabetes in advanced liver disease: change of a paradigm. <i>Annals of Hepatology</i> , 2023, 28, 100772.	1.5	4
544	Hypothalamic integrity is necessary for sustained weight loss after bariatric surgery: A prospective, cross-sectional study. <i>Metabolism: Clinical and Experimental</i> , 2023, 138, 155341.	3.4	7
545	The inflammatory proteome, obesity, and medical weight loss and regain in humans. <i>Obesity</i> , 2023, 31, 150-158.	3.0	4
546	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. <i>Obesity Facts</i> , 2023, 16, 149-163.	3.4	4
547	Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. <i>Nutrients</i> , 2022, 14, 4801.	4.1	5
549	Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	3.2	1

#	ARTICLE	IF	CITATIONS
550	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Diseaseâ€”Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842211463.	2.0	15
551	Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice. <i>Life Sciences</i> , 2023, 313, 121268.	4.3	5
552	Corrigendum to â€œMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ€• [Biochem. Pharmacol. 206 (2022) 115304]. <i>Biochemical Pharmacology</i> , 2023, 207, 115349.	4.4	0
553	Effects of once-weekly semaglutide 2.4Âmg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. <i>EClinicalMedicine</i> , 2023, 55, 101737.	7.1	8
554	Treating chronic diseases without tackling excess adiposity promotes multimorbidity. <i>Lancet Diabetes and Endocrinology</i> , 2023, 11, 58-62.	11.4	16
555	The association of multidimensional sleep health with adiposity in heart failure with preserved ejection fraction. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2023, 58, 144-151.	1.6	1
556	Diabetes in HIV: the Link to Weight Gain. <i>Current HIV/AIDS Reports</i> , 2023, 20, 9-18.	3.1	5
557	Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. <i>Cell Reports</i> , 2022, 41, 111698.	6.4	8
558	Physiology of the tongue with emphasis on taste transduction. <i>Physiological Reviews</i> , 2023, 103, 1193-1246.	28.8	12
559	Bariatric surgery and weight loss in the shortâ€•and longâ€•term: Evidence from <sc>NHANES</sc> 2015â€•2018. <i>Clinical Obesity</i> , 2023, 13, .	2.0	3
560	Obesity Treatment in Orthopaedic Surgery. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , 2022, 30, e1563-e1570.	2.5	3
561	Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes. , 2022, 1, .		0
562	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. <i>Nature Reviews Endocrinology</i> , 2023, 19, 151-163.	9.6	21
563	Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2022, 37, 65-72.	0.2	8
564	New therapies for obesity. <i>Cardiovascular Research</i> , 2024, 119, 2825-2842.	3.8	16
565	Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. <i>Nature Reviews Endocrinology</i> , 2023, 19, 201-216.	9.6	44
566	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 1882-1894.	1.6	58
567	Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagonâ€•like peptideâ€•1 receptor agonist<sc>BL</sc>456906. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1011-1023.	4.4	21

#	ARTICLE	IF	CITATIONS
568	Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	2.7	4
570	Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. <i>Clinical Epidemiology</i> , 0, Volume 14, 1463-1476.	3.0	10
571	Prevention of cardiorenal damage: importance of albuminuria. <i>European Heart Journal</i> , 2023, 44, 1112-1123.	2.2	12
572	GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. <i>Advances in Therapy</i> , 2023, 40, 723-742.	2.9	9
573	Semaglutide for cardiovascular event reduction in people with overweight or obesity: <sc>SELECT</sc> study baseline characteristics. <i>Obesity</i> , 2023, 31, 111-122.	3.0	31
574	Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). <i>Cureus</i> , 2022, , .	0.5	2
575	Marked weight loss on liraglutide 3.0Åmg: Real-life experience of a <sc>S</sc>wiss cohort with obesity. <i>Obesity</i> , 2023, 31, 74-82.	3.0	7
576	Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022. , 2022, 4, 100048.		7
577	Obesity in South and Southeast Asiaâ€”A new consensus on care and management. <i>Obesity Reviews</i> , 2023, 24, .	6.5	22
578	Horizon scan: State-of-the-art therapeutics for psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101809.	3.3	8
579	Fat â€“ pharmacological therapies. <i>British Journal of Diabetes</i> , 2022, 22, S59-S61.	0.2	0
580	Finding balance: understanding the energetics of time-restricted feeding in mice. <i>Obesity</i> , 2023, 31, 22-39.	3.0	5
581	3. Prevention or Delay of Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, S41-S48.	8.6	55
583	Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment. <i>World Journal of Diabetes</i> , 0, 13, 1096-1105.	3.5	2
586	Two decades of diabetes prevention efforts: A call to innovate and revitalize our approach to lifestyle change. <i>Diabetes Research and Clinical Practice</i> , 2023, 198, 110195.	2.8	8
587	Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 3961-3987.	2.4	5
588	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 63.	7.4	137
589	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. <i>Presse Medicale</i> , 2023, 52, 104160.	1.9	1

#	ARTICLE	IF	CITATIONS
590	Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 961-964.	4.4	7
591	Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2023, 30, 1-6.	2.3	1
592	Targeting inflammation to treat diabetic kidney disease: the road to 2030. <i>Kidney International</i> , 2023, 103, 282-296.	5.2	32
593	The Concept of Healthy Behaviours in Obesity May Have Unintended Consequences. <i>Nutrients</i> , 2023, 15, 12.	4.1	0
594	The “breakthrough” obesity drugs that have stunned researchers. <i>Nature</i> , 2023, 613, 16-18.	27.8	6
595	Pharmacologic management of weight regain following bariatric surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	7
597	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <i>Molecules</i> , 2023, 28, 751.	3.8	7
599	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	5
600	Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 855-867.	3.3	4
601	GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1703.	4.1	31
602	Pathophysiology of obesity and its associated diseases. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2403-2424.	12.0	27
603	Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom. <i>Advances in Therapy</i> , 2023, 40, 1282-1291.	2.9	3
604	46-Year-Old Woman With Type 2 Diabetes Mellitus and Obesity. <i>Mayo Clinic Proceedings</i> , 2023, 98, 181-186.	3.0	0
605	HIV and obesity: updates in management strategies. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 68-74.	3.8	3
606	Semaglutide in Obesity: Unmet Needs in Men. <i>Diabetes Therapy</i> , 0, .	2.5	3
607	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108389.	2.3	7
608	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2023, 43, 1-7.	2.1	3
609	Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. <i>Cancers</i> , 2023, 15, 485.	3.7	69

#	ARTICLE	IF	CITATIONS
610	Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 740-752.	0.9	15
611	Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 1066-1079.	0.9	4
612	Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery. , 2022, 1, .		0
613	Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. <i>Obesity Reviews</i> , 2023, 24, .	6.5	19
614	Genomics and phenomics of body mass index reveals a complex disease network. <i>Nature Communications</i> , 2022, 13, .	12.8	26
615	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4449-4461.	4.3	8
616	Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity. <i>Pulmonary Therapy</i> , 2023, 9, 71-89.	2.2	4
617	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. <i>Annual Review of Medicine</i> , 2023, 74, 125-139.	12.2	20
618	The Role of Primary Care in Bariatric Surgery. , 2023, , 1395-1408.		0
619	Evidence Base for Bariatric Surgery. , 2023, , 103-119.		0
620	Roadmap for Achieving Universal Antiretroviral Treatment. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 99-117.	9.4	2
621	Medications for the treatment of obesity. <i>Journal of Visceral Surgery</i> , 2023, 160, S12-S14.	0.8	1
622	Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0278685.	2.5	9
623	Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?. <i>Cardiovascular Research</i> , 2024, 119, e167-e171.	3.8	5
624	The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 772.	2.4	4
625	<scp>Glucagon-like peptide</scp> -1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. <i>Obesity</i> , 2023, 31, 350-362.	3.0	3
626	Obesity among Latinx people in the United States: A review. <i>Obesity</i> , 2023, 31, 329-337.	3.0	12
628	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. <i>Nutrients</i> , 2023, 15, 687.	4.1	12



#	ARTICLE	IF	CITATIONS
629	Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. <i>Nutrients</i> , 2023, 15, 606.	4.1	1
630	The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2023, 24, .	6.5	3
631	A Multi-Ingredient Supplement Protects against Obesity and Infertility in Western Diet-Fed Mice. <i>Nutrients</i> , 2023, 15, 611.	4.1	1
633	Combined lifestyle interventions. , 2023, , 333-351.		0
634	Medical and surgical interventions to improve fertility outcomes. , 2023, , 95-103.		0
636	Medical therapy. , 2023, , 353-361.		0
638	Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. <i>International Journal of Obesity</i> , 0, , .	3.4	1
639	Weight Prediction Using the Hybrid Stacked-LSTM Food Selection Model. <i>Computer Systems Science and Engineering</i> , 2023, 46, 765-781.	2.4	4
640	Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission. <i>Cureus</i> , 2023, , .	0.5	0
641	Heart Disease and Stroke Statisticsâ€™2023 Update: A Report From the American Heart Association. <i>Circulation</i> , 2023, 147, .	1.6	2,130
642	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	7.3	358
643	Effect of bariatric surgery on the incidence of heart failure: A propensity score matched nationwide cohort study. <i>International Journal of Cardiology</i> , 2023, , .	1.7	1
644	Cardiometabolic risk factors efficacy of semaglutide in the STEP program. <i>Postgraduate Medicine</i> , 2022, 134, 18-27.	2.0	1
645	Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. <i>Postgraduate Medicine</i> , 2022, 134, 28-36.	2.0	1
646	The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches. , 2023, , 273-309.		0
647	Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. <i>Obesity Surgery</i> , 2023, 33, 1017-1025.	2.1	26
648	Current and emerging medications for the management of obesity in adults. <i>Medical Journal of Australia</i> , 2023, 218, 276-283.	1.7	5
649	Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.9	2

#	ARTICLE	IF	CITATIONS
650	Semaglutide: should the media slim down its enthusiasm?. <i>BMJ, The</i> , 0, , p624.	6.0	5
651	Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
652	Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review. <i>Journal of Education, Health and Sport</i> , 2023, 18, 23-33.	0.1	0
653	Contemporary medical, device, and surgical therapies for obesity in adults. <i>Lancet, The</i> , 2023, 401, 1116-1130.	13.7	88
654	Variation in responses to incretin therapy: Modifiable and non-modifiable factors. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
655	Prospective study of weight loss and all-cause-, cardiovascular-, and cancer mortality. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
656	Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review. <i>Adverse Drug Reaction Bulletin</i> , 2023, 339, 1315-1318.	0.5	1
657	Practical guideline on obesity care in patients with gastrointestinal and liver diseases â€“ Joint ESPEN/UEG guideline. <i>Clinical Nutrition</i> , 2023, 42, 987-1024.	5.0	4
658	Remission of type 2 diabetes: A critical appraisal. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
659	Management of diabetes: Current concepts. <i>World Journal of Diabetes</i> , 0, 14, 396-411.	3.5	10
660	Novel therapeutics in rare genetic obesities: A narrative review. <i>Pharmacological Research</i> , 2023, 191, 106763.	7.1	2
661	Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2023, 27, 211-223.	2.1	6
662	Adolescent PCOS: a postpubertal central obesity syndrome. <i>Trends in Molecular Medicine</i> , 2023, 29, 354-363.	6.7	17
663	Current Treatment Options, Including Diet, Exercise, and Medications. <i>Clinics in Liver Disease</i> , 2023, 27, 397-412.	2.1	0
664	Obesity and Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 317-339.	3.2	9
665	Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 185, 106422.	4.0	5
666	Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?. <i>Cardiac Failure Review</i> , 0, 9, .	3.0	1
667	Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2023, 160, 137-162.	3.1	3

#	ARTICLE	IF	CITATIONS
668	The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1 obesity trials. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2142-2150.	4.4	0
669	Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets. <i>Molecular Metabolism</i> , 2023, 72, 101718.	6.5	5
670	Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy. <i>Metabolism: Clinical and Experimental</i> , 2023, 142, 155531.	3.4	4
671	Semaglutide alleviates inflammation-induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes. <i>International Immunopharmacology</i> , 2023, 119, 110196.	3.8	2
672	Excess body weight: Novel insights into its roles in obesity comorbidities. <i>Seminars in Cancer Biology</i> , 2023, 92, 16-27.	9.6	21
673	Integrating semaglutide into obesity management – a primary care perspective. <i>Postgraduate Medicine</i> , 2022, 134, 37-49.	2.0	0
674	Efficacy and safety of semaglutide for weight management: evidence from the STEP program. <i>Postgraduate Medicine</i> , 2022, 134, 5-17.	2.0	12
675	Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. <i>Postgraduate Medicine</i> , 2022, 134, 1-4.	2.0	1
676	Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 455-461.	2.4	1
677	Dual gut hormone receptor agonists for diabetes and obesity. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	7
678	GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	20
679	Exogenous succinate impacts mouse brown adipose tissue mitochondrial proteome and potentiates body mass reduction induced by liraglutide. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2023, 324, E226-E240.	3.5	6
680	A Call to Reconceptualize Obesity Treatment in Service of Health Equity: Review of Evidence and Future Directions. <i>Current Obesity Reports</i> , 2023, 12, 24-35.	8.4	5
681	Do glucagon like peptide-1 receptor agonists lead to long-term weight loss?. <i>Evidence-Based Practice</i> , 2023, 26, 34-34.	0.0	0
682	Using genetic association data to guide drug discovery and development: Review of methods and applications. <i>American Journal of Human Genetics</i> , 2023, 110, 195-214.	6.2	35
683	Pharmacological Support for the Treatment of Obesity – Present and Future. <i>Healthcare (Switzerland)</i> , 2023, 11, 433.	2.0	6
684	Innovating in the field of weight loss. <i>British Journal of Surgery</i> , 2023, 110, 536-537.	0.3	0
685	Obesity-associated cancer risk reduction after metabolic surgery: insights from the SPLENDID study and the path forward. <i>Surgery for Obesity and Related Diseases</i> , 2023, 19, 788-793.	1.2	2

#	ARTICLE	IF	CITATIONS
686	Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women. <i>Medical Clinics of North America</i> , 2023, 107, 285-298.	2.5	1
687	Hormonal Gut-Brain Signaling for the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3384.	4.1	8
688	Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2023, 21, 27-47.	0.8	0
689	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 25-45.	3.6	14
690	Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes. <i>Cardiovascular Endocrinology and Metabolism</i> , 2023, 12, e0279.	1.1	3
691	Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome. <i>Biomedicines</i> , 2023, 11, 496.	3.2	0
692	Eliminating Ambiguous Treatment Effects Using Estimands. <i>American Journal of Epidemiology</i> , 2023, 192, 987-994.	3.4	12
694	A conversation with Dr. Robert F. Kushner, MD, Professor of Medicine (Endocrinology) and Medical Education, Northwestern University Feinberg School of Medicine. <i>Journal of Clinical and Translational Science</i> , 2023, 7, .	0.6	0
696	Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. <i>Diabetes Care</i> , 2023, 46, 801-810.	8.6	13
697	USO DO MEDICAMENTO SEMAGLUTIDA COMO ALIADO NO TRATAMENTO DA OBESIDADE. <i>Recima21: Revista Científica Multidisciplinar</i> , 2023, 4, e422731.	0.0	1
699	Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , 2023, 11, 669.	3.2	3
700	Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. <i>Obesity</i> , 2023, 31, 1270-1279.	3.0	14
701	Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 407-418.	1.8	2
702	Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100477.	3.0	2
703	Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity. <i>Journal of Education, Health and Sport</i> , 2023, 13, 196-205.	0.1	0
704	Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic. <i>British Journal of Cancer</i> , 0, , .	6.4	3
705	How can physical activity facilitate a sustainable future? Reducing obesity and chronic disease. <i>Proceedings of the Nutrition Society</i> , 2023, 82, 286-297.	1.0	1
706	Current treatment landscape for obesity in Singapore. <i>Singapore Medical Journal</i> , 2023, 64, 172.	0.6	4

#	ARTICLE	IF	CITATIONS
707	Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. <i>Clinical Therapeutics</i> , 2023, 45, 248-261.	2.5	2
708	Impact of <scp>BMI</scp> and comorbidities on efficacy of onceâ€weekly semaglutide: Post hoc analyses of the <scp>STEP</scp> 1 randomized trial. <i>Obesity</i> , 2023, 31, 990-999.	3.0	3
709	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. <i>Journal of Hepatology</i> , 2023, 79, 538-551.	3.7	27
710	Pharmacological approaches to the prevention of type 2 diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	4
711	Fat mass, weight and body shape changes at menopause â€ causes and consequences: a narrative review. <i>Climacteric</i> , 2023, 26, 381-387.	2.4	3
713	Clinicopathological Characteristics and Risk Factors for Rapid eGFR Decline in Chinese Patients with Biopsy-Proven Obesity-Related Glomerulopathy. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 713-721.	2.4	1
714	Weighing in on the Scale of Justice for Equity and Access to Weight-Management Drugs. <i>Clinical Therapeutics</i> , 2023, , .	2.5	0
715	Effect of onceâ€weekly subcutaneous semaglutide 2.4Âmg on weightâ€and healthâ€related quality of life in an East Asian population: Patientâ€reported outcomes from the <scp>STEP</scp> 6 trial. <i>Clinical Obesity</i> , 2023, 13, .	2.0	1
716	Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	8
718	Obesity and Cardiovascular Risk. , 0, , .		0
719	GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 587-597.	1.8	10
720	Semaglutide 2Â4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 511-522.	8.1	83
721	Semaglutide in NASH-related cirrhosis: too late to the party?. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 494-495.	8.1	1
722	Disease-specific mortality and major adverse cardiovascular events after bariatric surgery: a meta-analysis of age, sex, and BMI-matched cohort studies. <i>International Journal of Surgery</i> , 2023, 109, 389-400.	2.7	2
723	Comment on: Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. <i>Surgery for Obesity and Related Diseases</i> , 2023, , .	1.2	0
724	Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. <i>Lancet Regional Health - Europe</i> , The, 2023, 29, 100617.	5.6	5
727	Point-of-Care Peptide Hormone Production Enabled by Cell-Free Protein Synthesis. <i>ACS Synthetic Biology</i> , 2023, 12, 1216-1226.	3.8	3
728	Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2023, 54, 158-165.	0.7	0

#	ARTICLE	IF	CITATIONS
729	Diabesity and the Kidney. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 168-207.	0.1	0
730	Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. <i>EClinicalMedicine</i> , 2023, 58, 101882.	7.1	65
731	Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention. <i>Healthcare (Switzerland)</i> , 2023, 11, 902.	2.0	15
732	Long-term Outcomes Following Adolescent Metabolic and Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2184-2192.	3.6	4
733	The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 385-395.	2.4	2
734	Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective. <i>Obesity Reviews</i> , 2023, 24, .	6.5	2
735	Adverse Events of GLP-1 Receptor Agonists for Weight Loss: Twitter and a National Pharmacovigilance Database. , 2023, 2, 41-48.		0
736	Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, , .	2.6	3
737	A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
738	Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6192.	4.1	19
740	A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of <sc>BI</sc> 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1973-1984.	4.4	4
741	Current pharmacotherapy options in pediatric obesity. <i>Cesko-Slovenska Pediatrie</i> , 2023, 78, 122-126.	0.2	2
742	SÅ©maglutide, vidange gastrique retardÃ©e et aspiration pulmonaire peropÃ©ratoire : une prÃ©sentation de cas. <i>Canadian Journal of Anaesthesia</i> , 2023, 70, 1394-1396.	1.6	36
743	The expanding incretin universe: from basic biology to clinical translation. <i>Diabetologia</i> , 2023, 66, 1765-1779.	6.3	26
744	GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2023, 77, 1-8.	0.1	0
745	How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion. <i>International Journal of Cardiology</i> , 2023, 381, 101-104.	1.7	1
746	Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. , 2023, , 365-396.		0
747	Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. <i>Molecules</i> , 2023, 28, 3094.	3.8	10

#	ARTICLE	IF	CITATIONS
748	The need to personalise approaches for the prevention and management of obesity. <i>EClinicalMedicine</i> , 2023, 58, 101944.	7.1	0
749	Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). <i>Swiss Medical Weekly</i> , 2023, 153, 40060.	1.6	5
750	Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. <i>Diabetes Therapy</i> , 0, , .	2.5	0
751	Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. <i>Human Reproduction</i> , 2023, 38, 1168-1182.	0.9	9
752	Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 1111-1120.	2.6	3
753	The risks and rewards of semaglutide in obesity treatment. <i>Journal of Prescribing Practice</i> , 2023, 5, 146-147.	0.1	0
754	Albuminuria and cardiorenal risk. <i>Current Opinion in Cardiology</i> , 0, Publish Ahead of Print, .	1.8	0
755	Global Impact of Obesity. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 277-293.	2.2	6
756	What is Obesity?. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 261-275.	2.2	5
757	Obesity in the USMLE Step 1 examination: A call to action. <i>International Journal of Obesity</i> , 0, , .	3.4	1
758	Semaglutide-eye-catching results. <i>World Journal of Diabetes</i> , 0, 14, 424-434.	3.5	2
760	New insights into the treatment of obesity. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2058-2072.	4.4	21
761	A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. <i>Life</i> , 2023, 13, 1012.	2.4	4
762	What Can the Health Humanities Contribute to Our Societal Understanding of and Response to the Deaths of Despair Crisis?. <i>Journal of Medical Humanities</i> , 0, , .	0.7	0
763	FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. <i>Cell Metabolism</i> , 2023, 35, 887-905.e11.	16.2	4
764	Potential contributors to variation in weight loss response to liraglutide. <i>Obesity Reviews</i> , 2023, 24, .	6.5	1
765	Tirzepatide: Clinical review of the "twincretin" injectable. <i>American Journal of Health-System Pharmacy</i> , 2023, 80, 879-888.	1.0	2
766	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1835-1878.	2.8	74

#	ARTICLE	IF	CITATIONS
767	Gene Therapy Based on Mesenchymal Stem Cells Derived from Adipose Tissue for the Treatment of Obesity and Its Metabolic Complications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7468.	4.1	5
768	Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. <i>Therapeutic Advances in Psychopharmacology</i> , 2023, 13, 204512532311651.	2.7	7
769	Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity. <i>ChemistrySelect</i> , 2023, 8, .	1.5	0
770	Ozempic face: A new challenge for facial plastic surgeons. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2023, 81, 97-98.	1.0	2
771	Insight into mitochondrial dysfunction mediated by clozapine-induced inhibition of PGRMC1 in PC12 cells. <i>Toxicology</i> , 2023, 491, 153515.	4.2	1
772	Design, synthesis, and biological evaluation of a potential long-acting glucagon-like peptide-1 (GLP-1) analog. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 85, 117291.	3.0	0
773	Bariatric – metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2023, 401, 1786-1797.	13.7	48
775	Semaglutide exposures reported to the <scp>NSW</scp> Poisons Information Centre: effects of social media marketing and supply chain disruptions. <i>Internal Medicine Journal</i> , 2023, 53, 654-655.	0.8	1
777	Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2023, 29, 564-568.	0.9	0
778	Medications for obesity management: Effectiveness and value. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2023, 29, 569-575.	0.9	0
779	Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. <i>Nature Reviews Cardiology</i> , 2023, 20, 685-695.	13.7	14
780	Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. <i>Internal Medicine Journal</i> , 2023, 53, 1311-1320.	0.8	2
781	Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease – Current Background, Hopes, and Perspectives. <i>Metabolites</i> , 2023, 13, 581.	2.9	2
782	Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. <i>Obesity</i> , 2023, 31, 1787-1797.	3.0	8
783	Liraglutide versus semaglutide for weight reduction – a cost needed to treat analysis. <i>Obesity</i> , 2023, 31, 1510-1513.	3.0	5
784	Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes. <i>IJC Heart and Vasculature</i> , 2023, 47, 101218.	1.1	1
785	General Treatment of Pediatric Obesity. , 2023, , 251-286.		0
786	Determinants of excessive weight gain after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 60). <i>Diabetes Research and Clinical Practice</i> , 2023, 200, 110719.	2.8	2



#	ARTICLE	IF	CITATIONS
787	A review of the evidence on cardiovascular outcomes from obesity treatment. , 2023, 7, 100071.		3
788	Clinical evaluation of patients living with obesity. Internal and Emergency Medicine, 0, , .	2.0	2
789	Editorial: “being normal weight each day keeps NAFLD and fibrosis away” the importance of reducing cumulative exposure to overweight. Authors' reply. Alimentary Pharmacology and Therapeutics, 2023, 57, 1168-1169.	3.7	0
790	Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology, 2023, 240, 1373-1386.	3.1	0
791	Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities. Journal of the National Cancer Institute Monographs, 2023, 2023, 68-76.	2.1	0
792	American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm “ 2023 Update. Endocrine Practice, 2023, 29, 305-340.	2.1	46
793	Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association. Circulation, 2023, 148, 74-94.	1.6	11
796	Overgewicht en obesitas. , 2023, , 345-359.		0
797	Anti-inflammatory Therapy for Cardiovascular Disease. , 2024, , 224-235.e1.		0
798	How to address weight regain after bariatric surgery in an individualized way. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 993-1002.	5.7	3
799	Role of flavonoids in controlling obesity: molecular targets and mechanisms. Frontiers in Nutrition, 0, 10, .	3.7	2
800	Stem Cell“Derived Islet Transplantation in Patients With Type 2 Diabetes: Can Diabetes Subtypes Guide Implementation?. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2772-2778.	3.6	1
801	Intestinal Enteroendocrine Cells: Present and Future Druggable Targets. International Journal of Molecular Sciences, 2023, 24, 8836.	4.1	2
802	Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. European Journal of Heart Failure, 2023, 25, 936-955.	7.1	20
803	Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC: Heart Failure, 2023, 11, 1000-1010.	4.1	16
804	Upper Airway Surgery or Weight Control? Modified Drug“Induced Sleep Endoscopy for Obstructive Sleep Apnea. Otolaryngology - Head and Neck Surgery, 2023, 169, 1345-1355.	1.9	1
805	Game-changing obesity drugs go mainstream: what scientists are learning. Nature, 2023, 618, 17-18.	27.8	2
807	Obesity-related hypertension. Nurse Practitioner, 2023, 48, 8-15.	0.3	0

#	ARTICLE	IF	CITATIONS
808	Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682311763.	2.2	0
809	Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2561-2574.	4.4	3
810	Pharmacotherapy for chronic obesity management: a look into the future. <i>Internal and Emergency Medicine</i> , 0, , .	2.0	0
811	Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 0, , ard-2023-223845.	0.9	5
812	Obesity: medical management. <i>Medicine</i> , 2023, 51, 509-514.	0.4	0
813	Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	5
814	Perspectives on weight control in diabetes – Tirzepatide. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110770.	2.8	4
815	Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?. <i>Journal of Arthroplasty</i> , 2023, 38, 2311-2315.e1.	3.1	3
816	The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. <i>Nature Metabolism</i> , 2023, 5, 945-954.	11.9	18
819	Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	6
820	Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. <i>Canadian Journal of Anaesthesia</i> , 2023, 70, 1397-1400.	1.6	22
821	Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	4
822	The sun is rising on a new era of pharmacotherapy for obesity: some words of caution. <i>Surgery for Obesity and Related Diseases</i> , 2023, , .	1.2	0
823	Editorial: Recent approaches in exploring metabolic inflammation. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2023, 26, 307-308.	2.5	0
824	Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD). <i>International Journal of Surgery Global Health</i> , 2023, 6, .	0.3	0
825	Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. <i>EBioMedicine</i> , 2023, 93, 104642.	6.1	13
827	Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	2
828	The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives. <i>Neurotherapeutics</i> , 2023, 20, 1229-1240.	4.4	0

#	ARTICLE	IF	CITATIONS
829	The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance. Journal of Diabetes and Its Complications, 2023, 37, 108517.	2.3	3
830	Psychological and medical treatments for binge-eating disorder: A research update. Physiology and Behavior, 2023, 269, 114267.	2.1	2
831	Reply to "New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy" Obesity Surgery, 0, , .	2.1	0
832	Hepatic protein kinase Cbeta deficiency mitigates late-onset obesity. Journal of Biological Chemistry, 2023, 299, 104917.	3.4	2
833	Obesity and Chronic Disease. , 2023, , 19-27.		1
834	Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 1767-1774.	2.4	2
835	Recent advancements in pharmacological strategies to modulate energy balance for combating obesity. RSC Medicinal Chemistry, 2023, 14, 1429-1445.	3.9	1
836	The invisible value of physical activity. Progress in Cardiovascular Diseases, 2023, , .	3.1	0
838	Improved health-related quality of life with semaglutide in people with nonalcoholic steatohepatitis: A randomised trial. Alimentary Pharmacology and Therapeutics, 2023, 58, 395-403.	3.7	3
839	Current and future pharmacotherapies for obesity in children and adolescents. Nature Reviews Endocrinology, 2023, 19, 534-541.	9.6	4
840	Partial Meal Replacement for Weight Loss after Stroke: Results of a Pilot Clinical Trial. Cerebrovascular Diseases, 2024, 53, 54-61.	1.7	1
842	New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy. Obesity Surgery, 0, , .	2.1	1
843	<sc>GLP</sc> agonists for people living with <sc>HIV</sc> and obesity, is there a potential?. HIV Medicine, 2023, 24, 1029-1034.	2.2	3
844	GLP-1 analogues in therapy of obese adolescents. Early real-life experience with liraglutide treatment. Cesko-Slovenska Pediatrie, 2023, 78, 176-181.	0.2	1
845	Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences, 2023, 24, 10449.	4.1	11
846	Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 2023, 389, 877-888.	27.0	61
847	Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. Journal of Obesity and Metabolic Syndrome, 2023, 32, 106-120.	3.6	6
848	Tirzepatide 10 and 15%mg compared with semaglutide 2.4%mg for the treatment of obesity: An indirect treatment comparison. Diabetes, Obesity and Metabolism, 2023, 25, 2626-2633.	4.4	6

#	ARTICLE	IF	CITATIONS
849	Long Term Complications of Immunosuppression Post Liver Transplant. Journal of Clinical and Experimental Hepatology, 2023, 13, 1103-1115.	0.9	1
850	CagriSema and the link between obesity and type 2 diabetes. Lancet, The, 2023, 402, 671-673.	13.7	1
851	Obesity and diabetes. Diabetes Research and Clinical Practice, 2023, 202, 110773.	2.8	10
852	Obesity and atrial fibrillation: Prevalence, pathogenesis, and prognosis. Progress in Cardiovascular Diseases, 2023, 78, 34-42.	3.1	7
853	Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction. Expert Review of Endocrinology and Metabolism, 2023, 18, 307-319.	2.4	5
854	Glucagon-Like Peptide-1 Receptors in the Gustatory Cortex Influence Food Intake. Journal of Neuroscience, 2023, 43, 4251-4261.	3.6	0
855	Cancer cachexia as a blueprint for treating obesity. Trends in Endocrinology and Metabolism, 2023, 34, 395-403.	7.1	1
856	Obesity: A Disease of Overnutrition. , 2023, , 85-95.		0
858	Severe, Complicated Pancreatitis With an Unclear Etiology. Cureus, 2023, , .	0.5	1
859	Semaglutide for weight management in adults. The Prescriber, 2023, 34, 29-31.	0.3	0
860	The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 2023, 8, .	5.0	21
861	Obesity wars: hypothalamic sEVs a new hope. Trends in Molecular Medicine, 2023, 29, 622-634.	6.7	3
862	Individualised prescription of medications for treatment of obesity in adults. Reviews in Endocrine and Metabolic Disorders, 0, , .	5.7	1
863	Health care providers' attitudes and counseling behaviors related to obesity. Obesity Science and Practice, 0, , .	1.9	0
864	Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice. Neuroscience Letters, 2023, 808, 137299.	2.1	0
865	Body weight time in target range and cardiovascular outcomes in adults with overweight/obesity and type 2 diabetes. European Journal of Preventive Cardiology, 0, , .	1.8	1
866	Obesity management for cardiovascular disease prevention. , 2023, 7, 100069.		3
867	Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase. Primary Care Diabetes, 2023, 17, 366-372.	1.8	2

#	ARTICLE	IF	CITATIONS
868	Heart Failure and Obesity: The Latest Pandemic. <i>Progress in Cardiovascular Diseases</i> , 2023, 78, 43-48.	3.1	7
869	Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms. <i>Nutrients</i> , 2023, 15, 2452.	4.1	2
870	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2022. <i>American Journal of Medicine</i> , 2023, , .	1.5	0
872	Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
873	Gut hormone co-agonists for the treatment of obesity: from bench to bedside. <i>Nature Metabolism</i> , 2023, 5, 933-944.	11.9	15
874	Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2023, 402, 613-626.	13.7	73
875	Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2023, 402, 705-719.	13.7	44
876	Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post- $\bar{a}$ bariatric treatment failure. <i>Clinical Obesity</i> , 2023, 13, .	2.0	6
877	Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions. <i>Archives of Endocrinology and Metabolism</i> , 2023, 67, .	0.6	2
879	Triple- $\bar{a}$ Hormone-Receptor Agonist Retatrutide for Obesity $\bar{a}$ A Phase 2 Trial. <i>New England Journal of Medicine</i> , 2023, 389, 514-526.	27.0	143
880	Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart $\bar{A}$ Failure. <i>JACC: Heart Failure</i> , 2023, , .	4.1	2
881	Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	2
882	Poria cocos compounds targeting neuropeptide Y1 receptor (Y1R) for weight management: A computational ligand- and structure-based study with molecular dynamics simulations identified beta-amyrin acetate as a putative Y1R inhibitor. <i>PLoS ONE</i> , 2023, 18, e0277873.	2.5	0
883	Shorter History of Hypertension as a Predictor of Hypertension Remission after 3-years of Bariatric Surgery: Data from the GATEWAY Trial. <i>Obesity Surgery</i> , 2023, 33, 2485-2492.	2.1	0
884	Effect of bariatric surgery on cardio-psycho-metabolic outcomes in severe obesity: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2023, 147, 155655.	3.4	3
885	Ketogenic diets for obesity $\bar{a}$ hypoventilation syndrome? Interesting physiology but a long way to go. <i>Respirology</i> , 2023, 28, 701-702.	2.3	1
886	Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. <i>Annals of the New York Academy of Sciences</i> , 2023, 1526, 16-29.	3.8	2
887	Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. <i>Aesthetic Surgery Journal</i> , 2023, 44, 60-67.	1.6	17

#	ARTICLE	IF	CITATIONS
888	Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 921-936.	5.7	2
889	GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Frontiers in Endocrinology, 0, 14, .	3.5	2
890	Tratamento farmacológico para obesidade no Brasil: drogas disponíveis, eficácia e custos associados. , 2023, 3, 55-62.		0
891	Eligibility for obesity management in Peru: Analysis of National Health Surveys from 2014 to 2022. Wellcome Open Research, 0, 8, 287.	1.8	0
892	Impact of nutritional and behavioral and supervised exercise intervention following bariatric surgery: The <sc>BARI-LIFESTYLE</sc> randomized controlled trial. Obesity, 2023, 31, 2031-2042.	3.0	4
893	Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. Canadian Journal of Cardiology, 2023, 39, 1816-1838.	1.7	2
894	The importance of fat-free mass and constituent tissue-organs in the control of human appetite. Current Opinion in Clinical Nutrition and Metabolic Care, 2023, 26, 417-422.	2.5	0
895	The Management of Obesity in 2023: An Update. , 0, , .		0
896	Neurobiology of eating behavior, nutrition, and health. Journal of Internal Medicine, 2023, 294, 582-604.	6.0	3
897	Semaglutide " effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP. Problemy Endokrinologii, 2023, 69, 68-82.	0.8	1
898	A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, Obesity and Metabolism, 2023, 25, 3171-3180.	4.4	0
899	Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2023, 24, 11271.	4.1	1
900	Weight gain after HIV therapy initiation: pathophysiology and implications. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	3
901	The Fatty Kidney and Beyond: A Silent Epidemic. American Journal of Medicine, 2023, 136, 965-974.	1.5	2
903	Current Role and Potential of Polymeric Biomaterials in Clinical Obesity Treatment. Biomacromolecules, 0, , .	5.4	0
904	Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity. American Journal of Therapeutics, 2023, 30, e347-e352.	0.9	3
905	Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022). European Journal of Clinical Pharmacology, 2023, 79, 1239-1248.	1.9	3
906	Are GLP-1R agonists the long-sought-after panacea for obesity?. Trends in Molecular Medicine, 2023, , .	6.7	0

#	ARTICLE	IF	CITATIONS
907	Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of SEMI (Spanish Society of Internal Medicine). <i>Revista Clínica Española</i> , 2023, 223, 493-498.	0.5	0
908	Novel <i>N</i> -Acylethanolamide Derivatives Affect Body Weight and Energy Balance. <i>Chemistry and Biodiversity</i> , 2023, 20, .	2.1	0
909	Breaking down silos: the multifaceted nature of obesity and the future of weight management. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2023, 378, .	4.0	2
910	Blockbuster Medications for Obesity: A Primer for Nephrologists. <i>American Journal of Kidney Diseases</i> , 2023, 82, 762-771.	1.9	0
911	Should Prediabetes be Treated Pharmacologically?. <i>Diabetes Therapy</i> , 2023, 14, 1585-1593.	2.5	1
912	Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST). <i>BJPsych Open</i> , 2023, 9, .	0.7	0
914	The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	2
916	Low Perception of Obesity as a Pathological Condition Among Italian Cardiologists. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2023, 30, 351-356.	2.2	1
917	Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery. <i>JAMA Surgery</i> , 2023, 158, 1003.	4.3	18
918	Obesity in the elderly: peculiarities of treatment in outpatient practice. <i>Obesity and Metabolism</i> , 2023, 20, 140-148.	1.2	0
919	Lifestyle interventions to change trajectories of obesity-related cardiovascular risk from childhood onset to manifestation in adulthood: a joint scientific statement of the task force for childhood health of the European Association of Preventive Cardiology and the European Childhood Obesity Group. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1462-1472.	1.8	5
920	The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review. <i>Aesthetic Surgery Journal</i> , 2023, 44, 68-79.	1.6	2
921	Semaglutide and cancer: A systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2023, 17, 102834.	3.6	6
922	Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Annals of Medicine</i> , 2023, 55, .	3.8	4
923	The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF. <i>JACC Basic To Translational Science</i> , 2023, 8, 1298-1314.	4.1	3
924	The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2023, 66, 1846-1858.	6.3	6
925	Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?. <i>Biomedicines</i> , 2023, 11, 2108.	3.2	7
926	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2023, 82, 833-955.	2.8	48

#	ARTICLE	IF	CITATIONS
927	Chemoprevention in hepatocellular carcinoma. <i>Current Hepatology Reports</i> , 2023, 22, 108-117.	0.9	0
930	Obesity-related hypertension and chronic kidney disease: from evaluation to management. <i>Kidney Research and Clinical Practice</i> , 2023, 42, 431-444.	2.2	1
931	Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 650.	7.4	5
932	Incretin Analogs for Weight Management in Adults Without Diabetes. <i>Annals of Pharmacotherapy</i> , 0, , .	1.9	0
933	Betaâ€œcell function in type 2 diabetes (<sc>T2DM</sc>): Can it be preserved or enhanced?. <i>Journal of Diabetes</i> , 0, , .	1.8	0
934	Management of hyperglycaemia in people with obesity. <i>Clinical Medicine</i> , 2023, 23, 364-371.	1.9	1
935	Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon. <i>Journal of Arthroplasty</i> , 2024, 39, 38-43.	3.1	1
936	Future therapies for obesity. <i>Clinical Medicine</i> , 2023, 23, 337-346.	1.9	4
937	Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension. <i>Current Opinion in Cardiology</i> , 2023, 38, 447-455.	1.8	1
938	Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 327.	1.6	0
939	Cardiovascular risk stratification among individuals with obesity: The Coronary Artery Calcium Consortium. <i>Obesity</i> , 2023, 31, 2240-2248.	3.0	1
940	Response to: Low-calorie Diets for Remission of Type 2 Diabetes--Do the Benefits Outweigh the Risks?. <i>Canadian Journal of Diabetes</i> , 2023, , , .	0.8	0
941	Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review. <i>Cell and Bioscience</i> , 2023, 13, .	4.8	2
942	Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023. , 2023, 8, 100083.		4
943	Review of Prediabetes. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 564.	7.4	0
944	The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. <i>American Journal of Clinical Nutrition</i> , 2023, 118, 614-626.	4.7	4
945	The energy-rush and insulin model of obesity. <i>Research Ideas and Outcomes</i> , 0, 9, .	1.0	0
946	Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?. <i>Current Cardiovascular Risk Reports</i> , 2023, 17, 155-165.	2.0	0



#	ARTICLE	IF	CITATIONS
947	PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats. <i>Neuropharmacology</i> , 2023, 239, 109686.	4.1	0
948	Cellular mechanism of diabetes remission by bariatric surgery. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 590-600.	7.1	1
949	US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	2
950	Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	5
951	The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide. <i>Diabetes Research and Clinical Practice</i> , 2023, 203, 110881.	2.8	1
952	GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications. <i>Cell Metabolism</i> , 2023, 35, 1519-1529.	16.2	18
953	Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Nonâ€“Small Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2023, 18, e99-e100.	1.1	1
954	NK cells vs. obesity: A tale of dysfunction & redemption. <i>Clinical Immunology</i> , 2023, 255, 109744.	3.2	0
955	Oral semaglutide: an OASIS from injectables. <i>Lancet, The</i> , 2023, 402, 670-671.	13.7	0
956	A narrative review of approved and emerging anti-obesity medications. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 101757.	2.7	4
958	Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. <i>New England Journal of Medicine</i> , 2023, 389, 1069-1084.	27.0	134
959	Dorothy Hodgkin lecture 2023: The enteroendocrine system—Sensors in your guts. <i>Diabetic Medicine</i> , 2023, 40, .	2.3	1
960	Semaglutide is effective in achieving weight loss in liver transplant recipients. <i>Liver Transplantation</i> , 0, , .	2.4	1
961	Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment. <i>Nutrients</i> , 2023, 15, 3737.	4.1	1
962	Down the Rabbit Hole: Reviewing the Evidence for Primary Prevention of Cardiovascular Disease in People with Obesity. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	0
963	HIV Treatment and Obesity: Whatâ€™s New?. <i>Infectious Diseases</i> , 0, , .	4.0	0
964	Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. <i>JAMA Network Open</i> , 2023, 6, e2329178.	5.9	4
965	Case Report: Semaglutide-associated depression: a report of two cases. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	3

#	ARTICLE	IF	CITATIONS
966	Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
967	Effect on Weight Loss of an Oral Supplement Containing Cinnamon Bark ( <i>Cinnamomum cassia</i> ) and <i>Withania somnifera</i> in Adult Patients with Overweight and Obesity: A Pilot Study. <i>J</i> , 2023, 6, 508-516.	0.9	0
968	Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Nutrients</i> , 2023, 15, 3693.	4.1	1
969	The promise of a new orally active body weight reducer. <i>European Heart Journal</i> , 2023, 44, 3403-3404.	2.2	0
970	Incretins and cardiovascular disease: to the heart of type 2 diabetes?. <i>Diabetologia</i> , 2023, 66, 1820-1831.	6.3	3
971	Obesity and psychological distress. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2023, 378, .	4.0	7
972	SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 322.	1.6	0
973	Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. <i>Gut</i> , 2024, 73, 246-254.	12.1	6
974	Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
975	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2023, 148, .	1.6	84
976	Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. <i>Biomedicines</i> , 2023, 11, 2498.	3.2	3
977	Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). <i>Current Urology Reports</i> , 0, , .	2.2	0
978	Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review. <i>JBMR Plus</i> , 2023, 7, .	2.7	0
979	Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study. <i>Pharmaceuticals</i> , 2023, 16, 1190.	3.8	1
980	A Systematic Approach to Treating Early Metabolic Disease and Prediabetes. <i>Diabetes Therapy</i> , 2023, 14, 1595-1607.	2.5	0
981	Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. <i>Facial Plastic Surgery</i> , 2023, 39, 719-721.	0.9	3
982	Metabolic and Bariatric Endoscopy: A Mini-Review. <i>Life</i> , 2023, 13, 1905.	2.4	1
983	A system approach to improving guideline-directed therapy for cardio-renal-metabolic conditions: The "beyond diabetes" initiative. <i>American Journal of Preventive Cardiology</i> , 2023, 16, 100608.	3.0	1

#	ARTICLE	IF	CITATIONS
984	Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide. <i>Nature Communications</i> , 2023, 14, .	12.8	0
985	Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial. <i>International Journal of Obesity</i> , 2023, 47, 1132-1142.	3.4	2
986	Therapeutics of Extracellular Vesicles in Cardiocerebrovascular and Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 187-205.	1.6	0
987	Obesity drug shortages are symptomatic of wider malaise. <i>Lancet, The</i> , 2023, , .	13.7	2
988	Patient Evaluation and Surgical Staging. <i>Clinics in Plastic Surgery</i> , 2023, , .	1.5	0
989	Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2023, 13, 1460.	2.5	1
990	The Role of Endoscopy in the Management of Adolescent Bariatric Patients: A Primer For Pediatric Gastroenterologists. <i>Current Gastroenterology Reports</i> , 0, , .	2.5	0
991	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. <i>Nature Medicine</i> , 2023, 29, 2909-2918.	30.7	26
992	Brain-body communication in metabolic control. <i>Trends in Endocrinology and Metabolism</i> , 2023, , .	7.1	1
993	Phenotyping obesity: A focus on metabolically healthy obesity and metabolically unhealthy normal weight. <i>Diabetes/Metabolism Research and Reviews</i> , 2024, 40, .	4.0	4
994	Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy. <i>Pharmaceuticals</i> , 2023, 16, 1256.	3.8	1
995	A revolution in obesity treatment. <i>Nature Medicine</i> , 2023, 29, 2406-2408.	30.7	6
996	Hunger & satiety signals: another key mechanism involved in the NAFLD pathway. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
997	Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. , 2023, 251, 108549.		3
998	The role of sclerostin in lipid and glucose metabolism disorders. <i>Biochemical Pharmacology</i> , 2023, 215, 115694.	4.4	0
999	Introduction to the dietary management of obesity in adults. <i>Clinical Medicine</i> , 2023, 23, 304-310.	1.9	1
1000	Assessment and management of chronic kidney disease in people living with obesity. <i>Clinical Medicine</i> , 2023, 23, 353-356.	1.9	2
1001	Medical management of obesity. <i>Clinical Medicine</i> , 2023, 23, 323-329.	1.9	1

#	ARTICLE	IF	CITATIONS
1002	Body Mass Index, Obesity, and Mortalityâ€”Part II. <i>Nutrition Today</i> , 2023, 58, 158-164.	1.0	1
1003	Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients. <i>Liver Transplantation</i> , 0, , .	2.4	1
1004	Four key questions on the new wave of anti-obesity drugs. <i>Nature</i> , 2023, 620, 28-30.	27.8	1
1005	Eligibility for obesity management in Peru: Analysis of National Health Surveys from 2014 to 2022. <i>Wellcome Open Research</i> , 0, 8, 287.	1.8	0
1006	Medications and conditions associated with weight loss in patients prescribed semaglutide based on realâ€”world data. <i>Obesity</i> , 2023, 31, 2482-2492.	3.0	2
1007	Effect of semaglutide 2.4 mg once weekly on 10â€”year type 2 diabetes risk in adults with overweight or obesity. <i>Obesity</i> , 2023, 31, 2249-2259.	3.0	2
1008	Obesidad : Un breve repaso a su tratamiento. <i>Revista De La Facultad De Medicina</i> , 2023, 1, 80-84.	0.0	0
1009	Commentary on: <i>Aesthetic Surgery Journal</i> Articles on Injectable Weight Loss Medications and Their Role in Plastic Surgery. <i>Aesthetic Surgery Journal</i> , 2023, 44, 80-83.	1.6	1
1011	Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness â€” a narrative review. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 1823-1832.	1.8	1
1012	Metformin Prescription for U.S. Veterans with Prediabetes, 2010-2019. <i>Journal of Investigative Medicine</i> , 0, , .	1.6	0
1013	Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?. <i>Sleep</i> , 2023, 46, .	1.1	2
1015	Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery. <i>Metabolism: Clinical and Experimental</i> , 2023, 148, 155689.	3.4	7
1017	Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. <i>Molecular Metabolism</i> , 2023, 78, 101801.	6.5	7
1018	Pharmacotherapy of Obesity: An Updated Overview. <i>Journal for Nurse Practitioners</i> , 2023, 19, 104750.	0.8	0
1019	Obesity increases the surgical complexity and risk of recurrence after midline primary ventral hernia repair: results on 2307 patients from the French Society of hernia surgery (SFCP-CH) registry database. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 0, , .	2.0	0
1021	Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 719-742.	4.7	1
1022	Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. <i>Journal of Hypertension</i> , 2024, 42, 23-49.	0.5	9
1024	Acupuncture as multi-targeted therapy for the multifactorial disease obesity: a complex neuro-endocrine-immune interplay. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0

#	ARTICLE	IF	CITATIONS
1025	Strategies for Long-Term Weight Loss and Maintenance. Korean Journal of Family Practice, 2023, 13, 128-137.	0.3	0
1026	Endoscopic therapies for patients with obesity: a systematic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 8166-8177.	2.4	2
1027	Management of the Failing Pancreas Graft. , 2023, , 975-987.		0
1028	The Effective Use of Anti-obesity Medications. Gastroenterology Clinics of North America, 2023, , .	2.2	0
1029	Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine, 2024, 83, 392-398.	2.3	2
1031	Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 0, 29, 5327-5338.	3.3	2
1032	Non-monotone Exponential Time (NEXT) Model for the Longitudinal Trend of a Continuous Outcome in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2024, 58, 127-135.	1.6	0
1034	Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice. American Journal of Gastroenterology, 2023, , .	0.4	0
1035	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
1036	Obesity, Metabolic Syndrome, and Sleep Disorders. , 2023, , 1-20.		0
1037	Gut Hormones and Metabolic Syndrome. , 2023, , 1-16.		0
1038	Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations. Current Psychiatry Reports, 0, , .	4.5	0
1040	Evaluation of weight loss counsel for Osteoarthritis patients: A cross-sectional analysis of NHANES 2011â€“2018. Osteoarthritis and Cartilage, 2023, , .	1.3	1
1041	Obesity preclinical elective: a qualitative thematic analysis of student feedback. International Journal of Obesity, 0, , .	3.4	0
1042	Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction. European Heart Journal, 0, , .	2.2	0
1043	The role of dietary fat in obesity. , 2024, , 135-147.		0
1044	Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 166908.	3.8	0
1045	Management of Medication-Induced Weight Gain. Gastroenterology Clinics of North America, 2023, , .	2.2	0

#	ARTICLE	IF	CITATIONS
1046	Central Adiposity Increases Risk of Kidney Stone Disease through Effects on Serum Calcium Concentrations. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 1991-2011.	6.1	2
1047	Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future. <i>Lancet Diabetes and Endocrinology</i> , 2023, 11, 861-878.	11.4	5
1048	Dyslipidemia. , 2024, , 476-488.		0
1049	Obesity and Hypertension: Pathophysiology and Treatment. , 2024, , 413-426.		0
1050	An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review. <i>Cureus</i> , 2023, , .	0.5	0
1051	Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. <i>Cureus</i> , 2023, , .	0.5	0
1052	Diet, Exercise, and Behavior Therapy. , 2023, , 1-19.		0
1053	A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2023, 148, 1636-1664.	1.6	14
1054	Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. <i>Psychiatry Research</i> , 2023, 330, 115539.	3.3	1
1055	Obesity, metabolic health and clinical outcomes after incident cardiovascular disease: A nationwide population-based cohort study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 0, , .	7.3	0
1056	The Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonist Drugs: A Comprehensive Literature Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2023, 11, 286-292.	0.2	0
1057	Proportion of caloric restriction-induced weight loss as skeletal muscle. <i>Obesity</i> , 2024, 32, 32-40.	3.0	0
1058	Anti-obesity drugs's side effects: what we know so far. <i>Nature</i> , 2023, 622, 682-682.	27.8	0
1059	The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, , 189000.	7.4	0
1060	Severe hypertriglyceridemia: Existing and emerging therapies. , 2023, 251, 108544.		3
1061	Keeping the weight off. <i>Nature Medicine</i> , 2023, 29, 2377-2378.	30.7	1
1062	Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2023, 149, 155710.	3.4	5
1063	High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	2

#	ARTICLE	IF	CITATIONS
1064	Euglycemic Diabetic Keto Acidosis in a Type 1 Diabetic Patient After Glucose Like Peptide-1 Administration: A Case Presentation. Journal of Investigative Medicine High Impact Case Reports, 2023, 11, .	0.6	0
1065	A machine learning framework for optimizing obesity care by simulating clinical trajectories and targeted interventions. Obesity, 2023, 31, 2665-2675.	3.0	0
1066	Novel <scp>cannabinoid receptor 1</scp> inverse agonist <scp>CRB</scp>â€913 enhances efficacy of tirzepatide, semaglutide, and liraglutide in the <scp>dietâ€nduced obesity</scp> mouse model. Obesity, 2023, 31, 2676-2688.	3.0	0
1067	A comparison of virtual and in person delivery of a full meal replacement program for obesity. Obesity Science and Practice, 2024, 10, .	1.9	0
1068	Fatty Acids Increase GDF15 and Reduce Food Intake Through a GFRAL Signaling Axis. Diabetes, 2024, 73, 51-56.	0.6	1
1070	Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding A.Âmuciniphila. Cell Reports Medicine, 2023, 4, 101235.	6.5	0
1071	Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity. Periodontology 2000, 0, , .	13.4	2
1072	What is new in diabetes care and self-management?. Nursing, 2023, 53, 10-11.	0.3	0
1073	Weight Loss Effect of GLP-1 RAs with Endoscopic Bariatric Therapy and Bariatric Surgeries. Journal of the Endocrine Society, 0, , .	0.2	0
1075	An updated patent review of GLP-1 receptor agonists (2020-present). Expert Opinion on Therapeutic Patents, 2023, 33, 597-612.	5.0	0
1076	Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases. Current Cardiology Reports, 0, , .	2.9	0
1077	Glucagon Like Peptide-1 Receptor Agonists in Type 1 Diabetes. Diabetes and Metabolism, 2023, , 101487.	2.9	0
1078	Liver biopsy for assessment of suspected drugâ€nduced liver injury in metabolic dysfunctionâ€associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Alimentary Pharmacology and Therapeutics, 2024, 59, 201-216.	3.7	0
1079	Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller. , 0, , .		0
1080	Medikamente zur Behandlung von EssstÃ¶rungen und Adipositas. , 2023, , 803-829.		0
1081	Semaglutide: a new drug for the treatment of obesity. Drug and Therapeutics Bulletin, 2023, 61, 182-188.	0.3	3
1082	The pathogenesis of obesity in people living with HIV. Current Opinion in HIV and AIDS, 2024, 19, 6-13.	3.8	0
1083	Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opinion on Investigational Drugs, 2023, 32, 1003-1008.	4.1	0

#	ARTICLE	IF	CITATIONS
1084	Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes. JAMA Network Open, 2023, 6, e2339337.	5.9	2
1085	Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	2
1086	Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review. Seminars in Reproductive Medicine, 0, , .	1.1	0
1087	Semaglutide in NASH-related Compensated Cirrhosis: Is There a Silver Lining?. Journal of Clinical and Experimental Hepatology, 2023, 13, 1144-1145.	0.9	0
1088	Sequential appetite suppression by oral and visceral feedback to the brainstem. Nature, 2023, 624, 130-137.	27.8	2
1089	Enteroendocrine cell regulation of the gut-brain axis. Frontiers in Neuroscience, 0, 17, .	2.8	4
1090	Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based coagonists. Obesity Reviews, 2024, 25, .	6.5	0
1091	Anti-obesity pharmacotherapy in adults with chronic kidney disease. Kidney International, 2023, , .	5.2	1
1092	Serotonin receptor 4 agonism prevents high fat diet induced reduction in GLP-1 in mice. European Journal of Pharmacology, 2023, 960, 176181.	3.5	1
1093	Is obesity the next step in evolution through brain changes?. , 2024, 3, 103927.		0
1094	Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. Diabetes, Obesity and Metabolism, 2024, 26, 690-698.	4.4	0
1095	Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control. Frontiers in Endocrinology, 0, 14, .	3.5	1
1096	Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction. Circulation: Heart Failure, 2023, 16, .	3.9	0
1097	Hypothalamic Supramammillary Control of Cognition and Motivation. Journal of Neuroscience, 2023, 43, 7538-7546.	3.6	1
1098	Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size. , 2023, 8, 100094.		0
1099	Efficacy and safety of semaglutide 2.4%mg according to antidepressant use at baseline: A post hoc subgroup analysis. Obesity, 0, , .	3.0	0
1100	Semaglutide 2.4%mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity, 2024, 32, 50-58.	3.0	2
1101	Use and continuity of weight-modifying medications among adults with diabetes and overweight/obesity: US population study. Obesity, 2023, 31, 2924-2935.	3.0	3



#	ARTICLE	IF	CITATIONS
1102	Provider beliefs and practices regarding the management of obesity in lung transplant recipients. , 2024, 3, 100028.		0
1103	A closer look at weight loss interventions in primary care: a systematic review and meta-analysis. Frontiers in Medicine, 0, 10, .	2.6	0
1104	The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports, 2023, 12, 453-473.	8.4	5
1105	What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients, 2023, 15, 4809.	4.1	1
1106	SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors. Biomedicine and Pharmacotherapy, 2024, 170, 115586.	5.6	1
1107	Glycoprotein Non-Metastatic Protein B (GPNMB): The Missing Link Between Lysosomes and Obesity. Experimental and Clinical Endocrinology and Diabetes, 2023, 131, 639-645.	1.2	0
1108	Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management. Cell Reports Medicine, 2023, 4, 101292.	6.5	0
1109	Obesity and Metabolic Syndrome in the United States. , 2023, , 1-18.		0
1110	Metabolically unhealthy obesity, sarcopenia and their interactions in obesity pathophysiology and therapeutics: Room for improvement in pharmacotherapy. Metabolism: Clinical and Experimental, 2023, 149, 155714.	3.4	0
1111	Weight to go!â€”Glucagon-like peptide 1 receptor agonists in liver transplant recipients. Liver Transplantation, 0, , .	2.4	0
1112	Obesity and In Vitro Fertilization. Seminars in Reproductive Medicine, 0, , .	1.1	0
1113	[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. Actas Dermo-sifiligrÃ¡ficas, 2023, , .	0.4	0
1114	GORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists. Gut, 2024, 73, 211-212.	12.1	0
1115	Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review. Metabolism: Clinical and Experimental, 2024, 151, 155721.	3.4	0
1117	Optimizing the prelung transplant candidate. Current Opinion in Organ Transplantation, 0, , .	1.6	0
1118	Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNTâ€™1 post hoc analysis. Diabetes, Obesity and Metabolism, 2024, 26, 319-328.	4.4	3
1119	Impact of a pharmacist-led weight management service in a cardiology clinic. Journal of the American Pharmacists Association: JAPhA, 2024, 64, 557-563.	1.5	0
1120	Effects of <sc>CB1R</sc> inverse agonist, <sc>INV</sc>â€™202, in patients with features of metabolic syndrome. A randomized, placeboâ€™controlled, doubleâ€™blind phase 1b study. Diabetes, Obesity and Metabolism, 2024, 26, 642-649.	4.4	0

#	ARTICLE	IF	CITATIONS
1121	Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 782-784.	4.4	3
1122	Retatrutide showing promise in obesity (and type 2 diabetes). <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 997-1001.	4.1	0
1123	Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom. <i>Applied Health Economics and Health Policy</i> , 0, , .	2.1	0
1124	The cardiovascular effects of novel weight loss therapies. <i>European Heart Journal</i> , 2023, 44, 5036-5048.	2.2	5
1125	Beyond pounds: What else could be lost?. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108649.	2.3	0
1126	Cardiovascular Health of Middle-Aged U.S. Adults by Income Level, 1999 to March 2020. <i>Annals of Internal Medicine</i> , 2023, 176, 1595-1605.	3.9	2
1127	Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism. <i>MedComm</i> , 2023, 4, .	7.2	0
1128	FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. <i>EClinicalMedicine</i> , 2023, 66, 102310.	7.1	2
1129	Seeking satiety: From signals to solutions. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
1130	Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond. <i>Metabolism: Clinical and Experimental</i> , 2024, 151, 155741.	3.4	1
1132	Insulin-Dendrimer Nanocomplex for Multi-Day Glucose-Responsive Therapy in Mice and Swine. <i>Advanced Materials</i> , 0, , .	21.0	0
1133	Effective Anti-Obesity Drugs Make Losing Weight a Big Deal. <i>Engineering</i> , 2023, , .	6.7	0
1134	Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?. <i>Biomolecules</i> , 2023, 13, 1695.	4.0	0
1135	Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models. <i>Hepatology Communications</i> , 2023, 7, .	4.3	0
1136	The relation between excess adiposity and breast cancer in women: Clinical implications and management. <i>Critical Reviews in Oncology/Hematology</i> , 2024, 193, 104213.	4.4	0
1137	Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. <i>European Journal of Internal Medicine</i> , 2023, , .	2.2	4
1139	Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. <i>Endocrine Practice</i> , 2024, 30, 160-171.	2.1	3
1140	Obesity Management in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 2000.	7.4	8

#	ARTICLE	IF	CITATIONS
1141	Considerations of delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists. Medical Journal of Australia, 0, , .	1.7	0
1142	Efficacy and safety of semaglutide 2.4%mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year <sc>STEP</sc> 5 trial. Diabetes, Obesity and Metabolism, 2024, 26, 911-923.	4.4	1
1143	For Appetite Control, Drugs vs Diet. American Journal of Medicine, 2024, 137, 198-199.	1.5	0
1145	Comment on Frampton etÂal. 2023: Propionate, not acetate, lactate or succinate, may explain carbohydrate effects on satiety. Journal of Physiology, 0, , .	2.9	1
1146	Drug Therapies for Diabetes. International Journal of Molecular Sciences, 2023, 24, 17147.	4.1	1
1148	Earlyand <sc>laterstage</sc> persistence with <sc>antiobesity</sc> medications: A retrospective cohort study. Obesity, 2024, 32, 486-493.	3.0	2
1149	Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation. Transplantation, 0, , .	1.0	0
1150	SURMOUNTing body weight barriers in type 2 diabetes. Med, 2023, 4, 849-851.	4.4	0
1151	CONSUMO DE PREBIÓTICOS, PROBIÓTICOS E TERAPIA FARMACOLÓGICA E SUA RELAÇÃO COM A MODULAÇÃO DO INTESTINAL NO TRATAMENTO DA OBESIDADE: UMA REVISÃO DA LITERATURA. , 2023, 3, 26533-26553.		0
1152	A class of secreted mammalian peptides with potential to expand cell-cell communication. Nature Communications, 2023, 14, .	12.8	1
1153	Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA - Journal of the American Medical Association, 2024, 331, 38.	7.4	21
1154	MASLD treatmenta shift in the paradigm is imminent. Frontiers in Medicine, 0, 10, .	2.6	0
1155	3. Prevention or Delay of Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetesâ€2024</i>. Diabetes Care, 2024, 47, S43-S51.	8.6	1
1156	Expanding the Use of Medications for Alcohol Use Disorder: Lessons from the Proliferation of Anti-obesity Medications. Journal of General Internal Medicine, 0, , .	2.6	0
1157	Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss. Aesthetic Surgery Journal, 0, , .	1.6	0
1158	High-calorie diets uncouple hypothalamic oxytocin neurons from a gut-to-brain satiation pathway via Î-opioid signaling. Cell Reports, 2023, 42, 113305.	6.4	0
1160	Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges. Drugs, 2024, 84, 127-148.	10.9	0
1161	Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet. Journal of Clinical Gastroenterology, 0, , .	2.2	0

#	ARTICLE	IF	CITATIONS
1162	Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study. <i>Obesity Surgery</i> , 0, , .	2.1	0
1163	GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. <i>New England Journal of Medicine</i> , 2023, 389, 2303-2305.	27.0	0
1164	A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. <i>Nature Communications</i> , 2023, 14, .	12.8	2
1165	Doseâ€“response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. <i>Diabetologia</i> , 2024, 67, 470-482.	6.3	2
1166	Obesity, heart failure with preserved ejection fraction, and the role of glucagonâ€“like peptideâ€“1 receptor agonists. <i>ESC Heart Failure</i> , 0, , .	3.1	0
1167	Contemporary Clinical Perspectives on Targeting Remission of Type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
1168	Efficacy of noigliutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, doubleâ€“blind, placeboâ€“controlled, phase 2 trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1057-1068.	4.4	0
1169	Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions. <i>Journal of Arthroplasty</i> , 2024, 39, 716-720.	3.1	1
1170	High dose semaglutide 2.4 mg (once weekly) shown to reduce the risks of cardiovascular events in people without diabetes. <i>Diabetes Obesity and Metabolism Now</i> , 2023, 1, .	0.0	0
1171	A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. <i>Endocrine Practice</i> , 2024, 30, 292-303.	2.1	0
1172	Cardioâ€“renalâ€“metabolic disease in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 0, , .	4.0	1
1173	Quality over quantity â€“ Assessing the influence of body muscle composition on cardiovascular health. <i>American Journal of the Medical Sciences</i> , 2024, 367, 151-152.	1.1	0
1174	Consensus on pharmacological treatment of obesity in Latin America. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1175	A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart Disease Among Patients with Diabetes and/or Obesity. <i>Medical Clinics of North America</i> , 2024, 108, 469-487.	2.5	0
1176	Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?. <i>Current Heart Failure Reports</i> , 0, , .	3.3	0
1177	Use of glucagonâ€“like peptideâ€“1 receptor agonists in eating disorder populations. <i>International Journal of Eating Disorders</i> , 2024, 57, 286-293.	4.0	0
1179	Weight loss outcomes are generally worse for dogs and cats with class II obesity, defined asâ€“>â€“40% overweight. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
1180	Impact of GLP-1 Agonists on Male Reproductive Healthâ€“A Narrative Review. <i>Medicina (Lithuania)</i> , 2024, 60, 50.	2.0	1

#	ARTICLE	IF	CITATIONS
1181	Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
1182	KCNQ5 Controls Perivascular Adipose Tissueâ€‘Mediated Vasodilation. <i>Hypertension</i> , 2024, 81, 561-571.	2.7	0
1183	<sc>G</sc>lucagonâ€‘like peptideâ€‘1 analogues in monogenic syndromic obesity: Realâ€‘world data from a large cohort of AlstrÃ‘m syndrome patients. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 989-996.	4.4	1
1184	Weight Loss Interventions for Adults With Obesity-Related Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2024, 12, 840-847.	3.8	1
1185	Management of type 2 diabetes after metabolic bariatric surgery. <i>Mini-invasive Surgery</i> , 0, , .	0.5	0
1186	Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
1187	Vascular damage in systemic lupus erythematosus. <i>Nature Reviews Nephrology</i> , 2024, 20, 251-265.	9.6	1
1188	Pharmacotherapy for obesity: moving towards efficacy improvement. <i>Diabetology and Metabolic Syndrome</i> , 2024, 16, .	2.7	0
1189	Weight Loss Following Bariatric Surgery in People with or without Metabolic Syndrome: A 5-Year Observational Comparative Study. <i>Journal of Clinical Medicine</i> , 2024, 13, 256.	2.4	0
1190	Treatment effect of semaglutide 2.4â€‘%mg on healthâ€‘related quality of life from <sc>STEP</sc> 1 <sc>SFâ€‘6D</sc> derived from <sc>SF</sc>â€‘36 with Australian weights. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1171-1179.	4.4	0
1191	Association of semaglutide with risk of suicidal ideation in a real-world cohort. <i>Nature Medicine</i> , 2024, 30, 168-176.	30.7	7
1192	Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. <i>Cardiovascular Diabetology</i> , 2024, 23, .	6.8	1
1193	Enhancing Lifestyles in the Metabolic syndrome (ELM) multisite behavioral efficacy trial. Design and baseline cohort. <i>American Heart Journal</i> , 2024, 270, 136-155.	2.7	0
1194	The effects of incretinâ€‘based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and metaâ€‘analysis. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1195	GLP-1 agonists: A review for emergency clinicians. <i>American Journal of Emergency Medicine</i> , 2024, 78, 89-94.	1.6	0
1196	Obesogens: a unifying theory for the global rise in obesity. <i>International Journal of Obesity</i> , 2024, 48, 449-460.	3.4	0
1197	Non-canonical G protein signaling. , 2024, 255, 108589.		0
1198	New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk. <i>Diagnostics</i> , 2024, 14, 229.	2.6	1

#	ARTICLE	IF	CITATIONS
1199	Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?. <i>Pharmacological Research</i> , 2024, 200, 107058.	7.1	0
1200	Obesity, Metabolic Syndrome, and Sleep Disorders. , 2023, , 639-658.		0
1201	Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. <i>Molecular Metabolism</i> , 2024, 80, 101880.	6.5	1
1202	A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation. <i>JMIR Formative Research</i> , 0, 7, e53619.	1.4	0
1203	A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide. <i>Cureus</i> , 2024, , .	0.5	0
1204	Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?. <i>Current Obesity Reports</i> , 2024, 13, 132-140.	8.4	0
1205	Review article: Pharmacologic management of obesity â€œupdates on approved medications, indications and risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 475-491.	3.7	0
1206	Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?. <i>Journal of Arthroplasty</i> , 2024, 39, 277-282.	3.1	0
1207	Potential therapies for obesity management: Exploring novel frontiers. <i>Current Problems in Cardiology</i> , 2024, 49, 102382.	2.4	0
1208	Glucagon-like Peptide-1 Agonists. <i>JBJS Reviews</i> , 2024, 12, .	2.0	0
1209	Recent advances in peptide-based therapies for obesity and type 2 diabetes. <i>Peptides</i> , 2024, 173, 171149.	2.4	1
1210	An RNA-seq atlas of mouse brain areas during fasting and diet-induced obesity. <i>Scientific Data</i> , 2024, 11, .	5.3	0
1211	The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. <i>Pharmacy (Basel, Switzerland)</i> , 2024, 12, 11.	1.6	0
1213	Prevention of cardiorenal complications in people with type 2 diabetes and obesity. <i>Cell Metabolism</i> , 2024, 36, 338-353.	16.2	1
1214	Update on obesity, the obesity paradox, and obesity management in heart failure. <i>Progress in Cardiovascular Diseases</i> , 2024, 82, 34-42.	3.1	0
1216	Social media for obesity education: a general overview for the novice creator. <i>American Journal of Physiology - Advances in Physiology Education</i> , 2024, 48, 114-121.	1.6	0
1218	The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 17, 227-230.	2.4	0
1220	Effect of Semaglutide on High-Fat-Diet-Induced Liver Cancer in Obese Mice. <i>Journal of Proteome Research</i> , 2024, 23, 704-717.	3.7	0

#	ARTICLE	IF	CITATIONS
1221	Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies. <i>European Journal of Pediatrics</i> , 2024, 183, 1499-1508.	2.7	0
1222	Net prices of new antiobesity medications. <i>Obesity</i> , 2024, 32, 472-475.	3.0	0
1223	Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1150-1156.	4.4	1
1225	Exploring the Intricate Interplay Between Obesity and Atrial Fibrillation: Mechanisms, Management, and Clinical Implications. <i>Cardiology in Review</i> , 0, , .	1.4	0
1226	Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. <i>Current Problems in Cardiology</i> , 2024, 49, 102403.	2.4	0
1227	Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist <sc>G3215</sc>, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1479-1491.	4.4	0
1228	Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1346-1354.	4.4	1
1229	Chirurgie de la paroi abdominale ventrale chez le patient en situation d'obésité. , 2023, , 205-209.		0
1230	Role of newer anti-diabetes drugs in prediabetes: A systematic review. , 2024, , 393-406.		0
1231	Glucagon and the metabolic syndrome. , 2024, , 337-350.		0
1232	Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis. <i>Biomedicine and Pharmacotherapy</i> , 2024, 171, 116150.	5.6	0
1234	Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. <i>Gut</i> , 0, , gutjnl-2023-330962.	12.1	2
1235	Characterizing a new tool to manipulate area postrema GLP1R+ neurons across species. <i>Physiology and Behavior</i> , 2024, 276, 114474.	2.1	0
1236	Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass). <i>Lancet Regional Health - Europe</i> , The, 2024, 38, 100836.	5.6	1
1237	Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. <i>International Journal of Clinical Pharmacy</i> , 2024, 46, 488-495.	2.1	0
1238	2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. <i>Circulation</i> , 2024, 149, .	1.6	8
1239	Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2024, 12, e5516.	0.6	0
1240	Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment. <i>Children</i> , 2024, 11, 153.	1.5	0

#	ARTICLE	IF	CITATIONS
1241	Nonpharmacological, pharmacological, and surgical options for obesity-related cardiometabolic disorders. , 2023, , 339-369.		0
1242	Evaluating the Impact of Enhanced Recovery After Surgery Protocols on Surgical Outcomes Following Bariatric Surgeryâ€”A Systematic Review and Meta-analysis of Randomised Clinical Trials. Obesity Surgery, 2024, 34, 778-789.	2.1	0
1243	Association of patient characteristics and insurance type with <scp>anti-obesity</scp> medications prescribing and fills. Diabetes, Obesity and Metabolism, 2024, 26, 1687-1696.	4.4	0
1244	Effects of physical form of <i>Î²</i>-lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans: a randomised crossover trial. British Journal of Nutrition, 0, , 1-10.	2.3	0
1247	Perspective Chapter: Perioperative Considerations for Patients Undergoing Robotic Radical Prostatectomy. , 0, , .		0
1248	Public health perspective on new weight loss medications. BMJ, The, 0, , q196.	6.0	1
1249	Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF. Current Opinion in Cardiology, 2024, 39, 148-153.	1.8	0
1250	Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective. International Journal of Obesity, 2024, 48, 683-693.	3.4	0
1251	Gut Hormones and Metabolic Syndrome. , 2023, , 357-372.		0
1252	Diet, Exercise, and Behavior Therapy. , 2023, , 695-712.		0
1253	Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics. Cancers, 2024, 16, 624.	3.7	0
1255	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
1256	Perioperative Considerations for Patients on Semaglutide. Current Anesthesiology Reports, 0, , .	2.0	0
1257	Obesity and Metabolic Syndrome in the United States. , 2023, , 15-32.		0
1258	Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. Sci, 2024, 6, 9.	3.0	0
1259	The effect of bariatric surgery type on cardiac reverse remodelling. International Journal of Obesity, 0, , .	3.4	0
1260	Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide. Farmatsiya I Farmakologiya, 2024, 11, 324-346.	0.6	0
1261	What is the pipeline for future medications for obesity?. International Journal of Obesity, 0, , .	3.4	1



#	ARTICLE	IF	CITATIONS
1262	Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. <i>International Journal of Obesity</i> , 2024, 48, 662-667.	3.4	0
1263	Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?. <i>Expert Opinion on Pharmacotherapy</i> , 2024, 25, 131-138.	1.8	0
1264	<sc>Bardetâ€Biedl</sc> syndrome: A focus on genetics, mechanisms and metabolic dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 13-24.	4.4	0
1266	Highlights in the clinical nutrition literature: A critical appraisal of current research. <i>Journal of Parenteral and Enteral Nutrition</i> , 2024, 48, 377-388.	2.6	0
1267	Obesity and Overweight: The â€œElephant in the Roomâ€•That We can No Longer Ignore: Time to SELECT Treatments. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2024, 31, 3-6.	2.2	0
1268	Treat Obesity to Treat Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2024, 15, 611-622.	2.5	0
1269	Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention. <i>European Heart Journal</i> , 2024, 45, 1392-1394.	2.2	0
1270	Abdominal donor-site complications following autologous breast reconstruction: A multi-institutional multisurgeon study. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2024, 90, 88-94.	1.0	0
1271	Glucagonâ€™a new player in weight management therapeutics?. <i>Lancet Diabetes and Endocrinology</i> ,the, 2024, 12, 150-151.	11.4	0
1272	Efficacy and safety of once weekly semaglutide 2Â•4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2024, 12, 184-195.	11.4	1
1273	Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years. <i>Journal of the American College of Cardiology</i> , 2024, 83, 637-648.	2.8	2
1274	Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index â‰¥27 kg/m <sup>2</sup> : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. <i>Hypertension</i> , 2024, 81, .	2.7	1
1275	Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2024, 12, 162-173.	11.4	3
1276	A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. <i>Nature Metabolism</i> , 2024, 6, 290-303.	11.9	2
1277	Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice. <i>Clinical Science</i> , 2024, 138, 173-187.	4.3	0
1278	Sarcopenic obesity in older adults: a clinical overview. <i>Nature Reviews Endocrinology</i> , 2024, 20, 261-277.	9.6	0
1279	Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States. <i>Cancers</i> , 2024, 16, 684.	3.7	0
1280	Counting the lifetime cost of obesity: Analysis based on national <sc>England</sc> data. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1464-1478.	4.4	0

#	ARTICLE	IF	CITATIONS
1281	The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. Patient Preference and Adherence, 0, Volume 18, 373-382.	1.8	1
1282	Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews, 2024, 25, .	6.5	0
1283	Effects of dietary fibre on metabolic health and obesity. Nature Reviews Gastroenterology and Hepatology, 2024, 21, 301-318.	17.8	0
1285	Semaglutide Misuse in Atypical Anorexia Nervosa—A Case Report. Journal of Clinical Psychopharmacology, 2024, 44, 179-180.	1.4	0
1286	Obesity management: sex-specific considerations. Archives of Gynecology and Obstetrics, 2024, 309, 1745-1752.	1.7	0
1287	Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Frontiers in Endocrinology, 0, 15, .	3.5	0
1288	Semaglutide 2.4Âmg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE). Obesity Science and Practice, 2024, 10, .	1.9	0
1289	Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0Âmg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial. Lancet Regional Health - Europe, The, 2024, 39, 100853.	5.6	0
1290	The double burden: Navigating type 1 diabetes and obesity. Clinical Obesity, 0, , .	2.0	0
1291	Sex-Specific Cardiometabolic Determinants of Postoperative Atrial Fibrillation After Cardiac Surgery. Canadian Journal of Cardiology, 2024, , .	1.7	0
1292	What is the evidence regarding the safety of new obesity pharmacotherapies. International Journal of Obesity, 0, , .	3.4	0
1293	Epithelial metabolism as a rheostat for intestinal inflammation and malignancy. Trends in Cell Biology, 2024, , .	7.9	0
1294	Drug approach to treatment for obesity in adults: perspectives and considerations. Revista Espanola De Enfermedades Digestivas, 2024, 116, .	0.3	0
1295	The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea. Obesity Reviews, 2024, 25, .	6.5	0
1296	Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid, 0, , .	4.5	0
1297	Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease. Diabetes, Obesity and Metabolism, 2024, 26, 3-12.	4.4	0
1298	Addressing the global obesity burden: a gender-responsive approach to changing food environments is needed. Proceedings of the Nutrition Society, 0, , 1-9.	1.0	0
1299	Methodological Insights and Future Directions in Gut Hormone Studies after Bariatric Metabolic Surgery: A Scoping Review. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1300	Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians. <i>Diabetes Spectrum</i> , 2024, 37, 39-47.	1.0	3
1301	The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2024, , .	4.4	0
1302	Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity. <i>JAMA Network Open</i> , 2024, 7, e2356183.	5.9	0
1303	Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?. <i>Gastrointestinal Disorders</i> , 2024, 6, 180-190.	0.8	0
1304	Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study. <i>Diabetes Research and Clinical Practice</i> , 2024, 209, 111586.	2.8	0
1305	Scoping review of obesity interventions: Research frontiers and publication status. <i>IScience</i> , 2024, 27, 109240.	4.1	0
1306	Reducing the risk of atherosclerotic cardiovascular disease in people with hemophilia: the importance of primary prevention. <i>Journal of Thrombosis and Haemostasis</i> , 2024, 22, 1304-1312.	3.8	0
1307	Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians. , 2024, 38, 31-35.		0
1308	Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments. <i>Patient Preference and Adherence</i> , 0, Volume 18, 435-454.	1.8	0
1309	Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage kidney disease. <i>Nephrology</i> , 0, , .	1.6	0
1310	Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. <i>Endocrinologia, Diabetes Y Nutrici�n</i> , 2024, 71, 124-132.	0.3	0
1311	Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. <i>EClinicalMedicine</i> , 2024, 69, 102475.	7.1	0
1312	Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer. <i>JACC: CardioOncology</i> , 2024, 6, 16-32.	4.0	0
1313	Total Joint Arthroplasty in Patients Who Are Obese or Morbidly Obese. <i>Journal of Bone and Joint Surgery - Series A</i> , 2024, 106, 659-664.	3.0	0
1314	Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to GLP1R gene region. <i>Genetic Epidemiology</i> , 0, , .	1.3	0
1315	Semaglutide and Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2024, 390, 766-769.	27.0	0
1316	Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing Ablation for Atrial Fibrillation (GOAL-AF) protocol. <i>Pilot and Feasibility Studies</i> , 2024, 10, .	1.2	0
1317	Perioperative management of patients on glucagon-like peptide-1 receptor agonists. <i>Current Opinion in Anaesthesiology</i> , 2024, 37, 323-333.	2.0	0

#	ARTICLE	IF	CITATIONS
1318	Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
1319	Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss. <i>Journal of Aesthetic Nursing</i> , 2024, 13, 6-12.	0.1	0
1320	Targeting the Natriuretic Peptide System to Improve Outcomes. <i>Journal of the American College of Cardiology</i> , 2024, 83, 915-917.	2.8	0
1321	Contemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications. <i>Translational Journal of the American College of Sports Medicine</i> , 2024, 9, .	0.6	0
1322	Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2024, 19, e0297488.	2.5	0
1323	Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. <i>Obesity Science and Practice</i> , 2024, 10, .	1.9	0
1324	Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2024, 33, 331-336.	2.0	0
1325	Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?. <i>Aids</i> , 2024, 38, 603-605.	2.2	0
1326	Impact of Glucagon-Like Peptide-1 Agonist Deprescription in Type-2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. <i>Diabetes Therapy</i> , 2024, 15, 843-853.	2.5	0
1327	Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management. <i>Cell Metabolism</i> , 2024, 36, 670-683.	16.2	0
1328	Turning fat into muscle: can this be an alternative to anti-obesity drugs such as semaglutide?. <i>Journal of Physiology</i> , 2024, 602, 1655-1658.	2.9	0
1329	Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment. <i>Science Advances</i> , 2024, 10, .	10.3	0
1330	Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition. <i>Cells</i> , 2024, 13, 380.	4.1	0
1331	Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study. <i>JGH Open</i> , 2024, 8, .	1.6	0
1332	Long-term Results of Duodeno-jejunal Bypass in the Treatment of Obesity and Type 2 Diabetes. <i>Obesity Surgery</i> , 2024, 34, 1407-1414.	2.1	0
1333	Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2961.	4.1	0
1334	Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report. <i>Cureus</i> , 2024, , .	0.5	0
1336	Weight-centric prevention of cancer. , 2024, 10, 100106.		0

#	ARTICLE	IF	CITATIONS
1337	Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. <i>Menopause</i> , 2024, 31, 266-274.	2.0	0
1339	Obesity and Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2024, 132, 232-239.	1.2	0
1340	Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. <i>International Journal of Obesity</i> , 0, , .	3.4	0
1341	Acquired hypothalamic obesity: A clinical overview and update. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 34-45.	4.4	0
1342	Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn. <i>International Journal of Obesity</i> , 0, , .	3.4	0
1343	One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction. <i>Med</i> , 2024, 5, 181-183.	4.4	0
1344	Acidosis and aspiration: Popular diabetes medications and the risks they pose in the perioperative period. <i>Journal of Clinical Anesthesia</i> , 2024, 95, 111416.	1.6	0
1345	Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes. <i>European Journal of Pharmacology</i> , 2024, 970, 176476.	3.5	0
1346	Relationship between body mass index and cardiometabolic health in a multi-ethnic population: A project baseline health study. <i>American Journal of Preventive Cardiology</i> , 2024, 18, 100646.	3.0	0
1347	Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology. <i>Atherosclerosis</i> , 2024, 392, 117523.	0.8	0
1348	Intestinal Acyl-CoA synthetase 5 (ACSL5) deficiency potentiates postprandial GLP-1 & PYY secretion, reduces food intake, and protects against diet-induced obesity. <i>Molecular Metabolism</i> , 2024, 83, 101918.	6.5	0
1349	Obesity: the perfect storm for heart failure. <i>ESC Heart Failure</i> , 0, , .	3.1	0
1350	Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice. <i>Drug Design, Development and Therapy</i> , 0, Volume 18, 845-858.	4.3	0
1351	A New Epoch in Treating Diseases of the Heart. <i>Journal of Clinical Lipidology</i> , 2024, 18, e5-e9.	1.5	0
1353	Current and Future Treatments of Vascular Cognitive Impairment. <i>Stroke</i> , 2024, 55, 822-839.	2.0	0
1354	Efficacy and safety of tirzepatide, <sc>GLP</sc>-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. <i>Obesity</i> , 2024, 32, 840-856.	3.0	0
1355	Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1356	Approach to Obesity Treatment in Primary Care. <i>JAMA Internal Medicine</i> , 0, , .	5.1	0

#	ARTICLE	IF	CITATIONS
1357	Blockbuster obesity drug leads to better health in people with HIV. <i>Nature</i> , 2024, 627, 477-478.	27.8	0
1358	Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches. <i>International Journal of Endocrinology</i> , 2024, 2024, 1-11.	1.5	0
1359	Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome, and Pulmonary Hypertension. <i>Sleep Medicine Clinics</i> , 2024, 19, 307-325.	2.6	0
1361	Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology. , 2024, 15, 24-37.		0
1362	CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. <i>Cardiovascular Diabetology</i> , 2024, 23, .	6.8	0
1363	Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD. <i>Obesity Surgery</i> , 2024, 34, 1471-1478.	2.1	0
1364	Practical strategies to manage obesity in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 2029-2045.	4.4	0
1365	Next Generation Weight Loss Drugs for the Prevention of Cancer?. <i>Cancer Control</i> , 2024, 31, .	1.8	0
1366	GLP-1R signaling modulates colonic energy metabolism, goblet cell number and survival in the absence of gut microbiota. <i>Molecular Metabolism</i> , 2024, 83, 101924.	6.5	0
1367	The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies. <i>Biomedicine and Pharmacotherapy</i> , 2024, 174, 116485.	5.6	0
1368	Effectiveness and safety of drugs for obesity. <i>BMJ, The</i> , 0, , e072686.	6.0	0
1369	Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 25-33.	4.4	0
1370	The association between previous use of <sc>anti-obesity</sc> medication and semaglutide weight loss outcomes. <i>Diabetes, Obesity and Metabolism</i> , 0, , .	4.4	0
1371	Semaglutide treatment for children with obesity: an observational study. <i>Archives of Disease in Childhood</i> , 0, , archdischild-2023-326687.	1.9	0
1372	GLP-1 Receptor Agonists and Gastrointestinal Adverse Eventsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 885.	7.4	0
1373	The knowns and unknowns of glucagon-like peptide 1 agonists and perioperative care. <i>Canadian Journal of Anaesthesia</i> , 0, , .	1.6	0
1374	Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 2209-2228.	4.4	0